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Invasive pneumococcal disease (IPD), caused by Streptococcus 
pneumoniae (pneumococcus), remains a leading cause of seri-
ous illness in children and adults worldwide (1). After routine 
infant immunization with a 7-valent pneumococcal conjugate 
vaccine (PCV7) began in 2000, IPD among children aged <5 
years in the United States decreased by 76%; however, IPD 
from non-PCV7 serotypes, particularly 19A, has increased (2). 
In February 2010, the Advisory Committee on Immunization 
Practices (ACIP) issued recommendations for use of a newly 
licensed 13-valent pneumococcal conjugate vaccine (PCV13) 
(3). PCV13 contains the seven serotypes in PCV7 (4, 6B, 9V, 
14, 18C, 19F, and 23F) and six additional serotypes (1, 3, 
5, 6A, 7F, and 19A). To characterize the potentially vaccine-
preventable IPD burden among children aged <5 years in the 
United States, CDC and investigators analyzed 2007 data from 
Active Bacterial Core surveillance (ABCs). This report summa-
rizes the results of that analysis, which found that among 427 
IPD cases with known serotype in children aged <5 years, 274 
(64%) were caused by serotypes contained in PCV13. In 2007, 
an estimated 4,600 cases of IPD occurred in children in this age 
group in the United States, including approximately 2,900 cases 
caused by serotypes covered in PCV13 (versus 70 cases caused 
by PCV7 serotypes). PCV13 use has the potential to further 
reduce IPD in the United States. Post-licensure monitoring 
will help characterize the effectiveness of PCV13 in different 
populations and track the potential changes in disease burden 
caused by non-PCV13 serotypes. 
ABCs* of the Emerging Infections Program (EIP) Network 
is a collaboration between CDC and 10 selected sites. ABCs 
conducts population- and laboratory-based active surveillance. 
During 2006 and 2007, IPD surveillance was conducted 
in Connecticut, Minnesota, and New Mexico, and selected 
counties in California, Colorado, Georgia, Maryland, New 
York, Oregon, and Tennessee. In 2007, the total catchment 
population of children aged <5 years for these 10 sites was 2.1 
million. A case of IPD was defined as isolation of S. pneumoniae 
from a normally sterile body site (primarily blood or cerebrospi-
nal fluid) in a resident of an ABCs area. Pneumococcal isolates 
were serotyped at CDC and reference laboratories. Serotype 
information was analyzed by vaccine serotype group (Table 1). 
Age-, race- and vaccine serotype-specific rates of IPD were 
calculated using observed IPD cases in the 2007 ABCs data as 
the numerator and U.S. Census Bureau projections of the 2007 
population of ABCs sites as the denominator. To estimate the 
incidence and total number of IPD cases in the United States 
in 2007, rates were standardized to the entire U.S. population, 
adjusting for small differences between age and race distribu-
tions of ABCs areas and the U.S. population. 
Investigators reviewed medical records to identify children 
aged 24–59 months with underlying medical conditions who 
are recommended by ACIP to receive the 23-valent pneumo-
coccal polysaccharide vaccine (PPSV23) (1). Characteristics of 
these high-risk children and healthy children were compared 
by chi-square test; data from 2006 and 2007 were summed 
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because of the small number of IPD cases with 
underlying medical conditions among persons in 
this age group.
In 2007, a total of 493 children aged <5 years 
(<60 months) with IPD were identified in the ABCs 
population (Table 2), and information on the sero-
type of the pneumococcal isolate was available for 
427 (87%) of those children. Among the 427, the 
group aged <12 months accounted for 36% of all 
cases, and the 12–23 months group accounted for 
29%. Overall rates were highest in children aged <12 
months and 12–23 months (40.5 and 31.2 cases per 
100,000 population, respectively); among children 
aged 24–59 months, rates of all IPD decreased with 
each additional year of age. Information on race was 
available for 378 (89%) cases for which serotype 
information was available. Among children aged <5 
years, rates of overall IPD in black children (35.8 cases 
per 100,000) and children of other races (30.7 cases 
per 100,000) were approximately twofold and 1.7-
fold higher, respectively, than rates for white children 
(18.4 per 100,000). 
Among the 427 IPD cases with known serotype 
in children aged <5 years, 274 (64%) were caused by 
serotypes contained in PCV13. Of these 274 cases, 
260 (95%) were caused by three of the six additional 
serotypes (3, 7F, and 19A) that are not included in 
PCV7; overall, 180 (42%) of the 427 were caused 
by serotype 19A. Within each 1-year age group, the 
proportions of all IPD cases caused by serotypes 
covered by PCV13 were relatively similar, ranging 
from 59% to 71%. The proportions of all IPD cases 
caused by the 13 serotypes were comparable in black 
children (61%), children of other races (62%), and 
white children (67%).
Information on hospitalization and clinical out-
come was available for 99% of serotyped IPD cases. 
Among 272 children with IPD caused by serotypes 
covered by PCV13 for whom hospitalization status, 
clinical presentation, and outcome were known, 168 
(62%) were hospitalized, and four (2%) died; 101 
(37%) had bacteremia without confirmed source, 24 
(9%) had meningitis, and 115 (42%) had pneumonia 
with bacteremia. 
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Based on the 2007 rate of IPD in children aged 
<5 years (22 cases per 100,000), an estimated 4,600 
cases of IPD occurred in this age group in the United 
States. Included among those cases were an estimated 
70 cases caused by serotypes covered in PCV7 and 
2,900 cases caused by serotypes covered in PCV13.
During 2006–2007, a total of 301 IPD cases with 
a known serotype occurred among children aged 
24–59 months; 31 cases (10%) occurred in a child at 
high risk recommended for vaccination with PPSV23 
(1). Of these 31 cases, the 11 serotypes included in 
PPSV23 but not in PCV13 (Table 1) accounted 
for four cases (13%), serotypes covered in PCV13 
accounted for 13 cases (42%), and the remaining 14 
cases (45%) were caused by serotypes not covered 
in either vaccine. PCV13 serotypes accounted for 
a smaller proportion of cases among children with 
underlying medical conditions than among healthy 
children aged 24–59 months (42% [13 of 31] versus 
65% [175 of 270]; p = 0.01).
Reported by
MM Farley, MD, Georgia Emerging Infections Program. 
S Petit, MPH, Connecticut Dept of Public Health, Emerging 
Infections Program. LH Harrison, MD, RA Hollick, MS, 
Johns Hopkins Bloomberg School of Public Health, Baltimore, 
Maryland. SM Zansky, PhD, New York State Dept of Health, 
Emerging Infections Program. K Gershman, MD, Colorado 
Dept of Public Health and Environment, W Schaffner, MD, 
B Barnes, T McMinn, Vanderbilt Univ School of Medicine, 
Nashville, Tennessee. A Thomas, Oregon Public Health Div. 
PD Kirley, MT, MPH, California Emerging Infections 
Program. J Baumbach, MD, New Mexico Dept of Health. 
C Lexau, PhD, Minnesota Dept of Health. J Henry, MSPH, 
B Beall, PhD, CG Whitney, MD, M Moore, MD, JP Nuorti, 
MD, Respiratory Diseases Br, Div of Bacterial Diseases, 
National Center for Immunization and Respiratory Diseases; 
JB Rosen, MD, EIS Officer, CDC. 
Editorial Note
Routine infant immunization with PCV7 since 
2000 has decreased rates of IPD in young children 
markedly, but IPD from non-PCV7 serotypes, 
TABLE 2. Number of cases and incidence of invasive pneumococcal disease (IPD), by age and serotype group, among children aged <5 years — 
Active Bacterial Core surveillance (ABCs), 10 U.S. sites, 2007*
Age (mos)
All IPD† PCV13 serotypes§ Non-PCV13 serotypes Serotype 19A
No. (%) Incidence No. (%) Incidence No. (%) Incidence No. (%) Incidence
<12  155 (36) 40.5 104 (38) 27.2 51  (33) 13.3 60  (33) 16.2
12–23 124 (29) 31.2 73 (27) 18.4 51  (33) 12.8 57  (32) 14.7
24–35 71 (17) 17.4 43 (16) 10.5 28  (18) 6.9 32  (18) 8.3
36–47 48 (11) 12.4 34 (12) 8.8 14  (9) 3.6 20  (11) 5.2
48–59 29 (7) 7.8 20 (7) 5.4 9  (6) 2.4 11  (6) 3.1
All <60 427 (100) 22 274 (100) 14.1 153  (100) 7.9 180  (100) 9.4
* Cases per 100,000 population. A case of IPD was defined as isolation of Streptococcus pneumoniae from a normally sterile body site (primarily blood or cerebrospi-
nal fluid) in a resident of an ABCs surveillance area. Sites include Connecticut, Minnesota, and New Mexico, and selected counties in California, Colorado, Georgia, 
Maryland, New York, Oregon, and Tennessee.
† Excludes cases missing serotypes (13%); a total of 493 IPD cases were identified among children aged <5 years.
§ The 13-valent pneumococcal conjugate vaccine (PCV13) includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
TABLE 1. Serotypes included in the three pneumococcal 





4 X X X
6B X X X
9V X X X
14 X X X
18C X X X
19F X X X


















* The 13-valent pneumococcal conjugate vaccine (PCV13) includes 
the seven serotypes in the 7-valent vaccine (PCV7) and six additional 
serotypes. The 23-valent pneumococcal polysaccharide vaccine 
(PPSV23) includes 12 of the serotypes included in PCV13 (it does 
not include serotype 6A) and 11 additional serotypes.
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predominantly serotype 19A, has increased and 
partially offset these reductions (2,4). Overall, rates of 
IPD have remained stable at 22–25 cases per 100,000 
since 2002 (2,4). Based on the findings in this report, 
the use of PCV13 in the routine immunization 
schedule has the potential to further reduce IPD 
caused by the six additional serotypes (1, 3, 5, 6A, 
7F, or 19A) among children aged <5 years. 
PPSV23 has been available for use in adults aged 
≥65 years and persons aged ≥2 years with certain 
underlying medical conditions since 1983 (1). In 
this analysis, approximately 42% of IPD cases among 
children aged 24–59 months with underlying medi-
cal conditions were caused by serotypes covered in 
PCV13; an additional 13% of cases were caused by 
serotypes not covered in PCV13 but included in 
PPSV23. The role for PPSV23 in high-risk children 
might become clearer when more data are available on 
disease burden and serotype distribution after routine 
use of PCV13. 
Based on available safety, immunogenicity and 
disease burden data, ACIP also recommends that a 
single supplemental PCV13 dose be given to healthy 
children aged 14–59 months and to children with 
underlying medical conditions up to age 71 months 
who already have completed a schedule of PCV7 (3). 
In one study, a single dose of PCV13 in children aged 
≥12 months who had received 3 previous doses of 
PCV7 induced an antibody response comparable to 
the 3-dose infant PCV13 series, and the safety profile 
of this supplemental dose was comparable to that 
after a fourth dose of PCV13 (5). Although rates of 
IPD are relatively low in these older children, ACIP 
also considered the emergence of multidrug-resistant 
serotype 19A strains causing meningitis and other 
severe invasive infections (6,7) and the substantial 
burden of noninvasive pneumococcal disease as 
additional factors in making the recommendation. 
Cost-effectiveness evaluations suggest that supple-
mental PCV13 vaccination appears comparable in 
cost effectiveness to other accepted interventions 
(CDC, unpublished data, 2009). 
After PCV7 was introduced, rates of IPD caused 
by the seven serotypes covered in the vaccine also 
decreased substantially among unvaccinated children 
and adults. This indirect (or herd) effect resulted from 
reduced nasopharyngeal carriage of pneumococcus 
in vaccinated children and reduced transmission 
from children to unvaccinated children and adults 
(8). Immunization of children with PCV13 also is 
anticipated to have herd effects among adults. For 
example, as of 2007, serotype 19A had emerged as 
the most common cause of IPD in all age groups after 
PCV7 introduction (CDC, unpublished data, 2009). 
Colonization and disease caused by serotype 19A have 
a similar epidemiological pattern to those caused by 
PCV7 serotypes, and some degree of herd effects in 
the population might be expected. In contrast, some 
of the other new serotypes in PCV13 might have dif-
ferent epidemiologic characteristics (9). In particular, 
serotypes 1 and 5 are rarely found in the nasopharynx, 
so the potential herd effects of PCV13 vaccination on 
disease caused by these serotypes is uncertain. In the 
United States, however, serotypes 1 and 5 are relatively 
uncommon causes of IPD.
Although rates of pneumonia hospitalizations 
decreased after PCV7 introduction among children 
aged <2 years (10), the potential effects of PCV13 on 
noninvasive disease, such as nonbacteremic pneumo-
nia and otitis media, are difficult to evaluate because of 
lack of standard case definitions, sensitive and specific 
diagnostic methods, and routine surveillance for these 
conditions. Information on these noninvasive pneu-
mococcal diseases is not available in the ABCs dataset. 
Because PCV13 was licensed on the basis of immu-
nogenicity studies rather than clinical efficacy trials, 
post-licensure monitoring is important to characterize 
What is already known on this topic?
In February 2010, a new 13-valent pneumococcal 
conjugate vaccine (PCV13) was licensed by the Food 
and Drug Administration and recommended by the 
Advisory Committee on Immunization Practices (ACIP) 
for prevention of invasive pneumococcal disease in 
children; PCV13 succeeds the 7-valent vaccine (PCV7) 
used in the routine childhood immunization schedule 
since 2000. 
What is added by this report?
In 2007, 64% of 427 invasive pneumococcal disease 
(IPD) cases observed in the Active Bacterial Core 
surveillance (ABCs) were caused by the serotypes cov-
ered by PCV13; 42% of cases were caused by serotype 
19A alone.  
What are the implications for public health practice?
Achieving and maintaining a high coverage of PCV13 
can further reduce IPD among children aged <5 years; 
postlicensure monitoring will help characterize the 
effectiveness of PCV13 and track the potential change 
in disease burden caused by non-PCV13 serotypes.
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the effectiveness of PCV13 in different populations 
and to track the potential changes in disease burden 
caused by non-PCV13 serotypes.
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On February 24, 2010, a 13-valent pneumococ-
cal conjugate vaccine (PCV13 [Prevnar 13, Wyeth 
Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) 
was licensed by the Food and Drug Administration 
(FDA) for prevention of invasive pneumococcal dis-
ease (IPD) caused by the 13 pneumococcal serotypes 
covered by the vaccine and for prevention of otitis 
media caused by serotypes in the 7-valent pneumococ-
cal conjugate vaccine formulation (PCV7 [Prevnar, 
Wyeth]). PCV13 is approved for use among children 
aged 6 weeks–71 months and succeeds PCV7, which 
was licensed by FDA in 2000. The Pneumococcal 
Vaccines Work Group of the Advisory Committee 
on Immunization Practices (ACIP) reviewed avail-
able data on the immunogenicity, safety, and cost-
effectiveness of PCV13, and on estimates of the 
vaccine-preventable pneumococcal disease burden. 
The working group then presented policy options for 
consideration of the full ACIP. This report summarizes 
recommendations approved by ACIP on February 
24, 2010, for 1) routine vaccination of all children 
aged 2–59 months with PCV13,  2) vaccination 
with PCV13 of children aged 60–71 months with 
underlying medical conditions that increase their 
risk for pneumococcal disease or complications, and 
3) PCV13 vaccination of children who previously 
received 1 or more doses of PCV7 (1). CDC guid-
ance for vaccination providers regarding transition 
from PCV7 to the PCV13 immunization program 
also is included.
Prevnar 13 Licensure
Vaccine formulation. PCV13 contains polysac-
charides of the capsular antigens of Streptococcus 
pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, and 23F, individually conjugated 
to a nontoxic diphtheria CRM197 (CRM, cross-
reactive material) carrier protein. A 0.5-mL PCV13 
dose contains approximately 2 μg of polysaccharide 
from each of 12 serotypes and approximately 4 μg 
of polysaccharide from serotype 6B; the total con-
centration of CRM197 is approximately 34 μg. The 
vaccine contains 0.125 mg of aluminum as aluminum 
phosphate adjuvant and no thimerosal preservative. 
PCV13 is administered intramuscularly and is avail-
able in single-dose, prefilled syringes that do not 
contain latex (2).
Immunogenicity profile. The immunogenicity 
of PCV13 was evaluated in a randomized, double-
blind, active-controlled trial in which 663 U.S. infants 
received at least 1 dose of PCV13 or PCV7 (3). To 
compare PCV13 antibody responses with those for 
PCV7, criteria for noninferior immunogenicity after 
3 and 4 doses of PCV13 (pneumococcal immuno-
globulin G [IgG] antibody concentrations measured 
by enzyme immunoassay) were defined for the seven 
serotypes common to PCV7 and PCV13 (4, 6B, 9V, 
14, 18C, 19F, and 23F) and for the six additional 
serotypes in PCV13 (serotypes 1, 3, 5, 6A, 7F, and 
19A). Functional antibody responses were measured 
by opsonophagocytosis assay (OPA) in a subset of the 
study population. Evaluation of these immunologic 
parameters indicated that PCV13 induced levels of 
antibodies that were comparable to those induced by 
PCV7 and shown to be protective against IPD (3).
Among infants receiving the 3-dose primary series, 
responses to three PCV13 serotypes (the shared sero-
types 6B and 9V, and new serotype 3) did not meet the 
prespecified, primary endpoint criterion (percentage 
of subjects achieving an IgG seroresponse of ≥0.35 μg/
mL 1 month after the third dose); however, detect-
able OPA antibodies to each of these three serotypes 
indicated the presence of functional antibodies (3). 
The percentages of subjects with an OPA titer ≥1:8 
were similar for the seven common serotypes among 
PCV13 recipients (range: 90%–100%) and PCV7 
recipients (range: 93%–100%); the proportion of 
PCV13 recipients with an OPA titer ≥1:8 was >90% 
for all of the 13 serotypes (3).
After the fourth dose, the IgG geometric mean 
concentrations (GMCs) were comparable for 12 of 
the 13 serotypes; the noninferiority criterion was not 
met for serotype 3. However, measurable OPA titers 
were present for all serotypes after the fourth dose; 
the percentage of PCV13 recipients with an OPA titer 
≥1:8 ranged from 97% to 100% for the 13 serotypes 
and was 98% for serotype 3 (3). 
Licensure of a 13-Valent Pneumococcal Conjugate Vaccine 
(PCV13) and Recommendations for Use Among Children — 
Advisory Committee on Immunization Practices (ACIP), 2010
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A schedule of 3 doses of PCV7 followed by 1 dose 
of PCV13 resulted in somewhat lower IgG GMCs for 
the six additional serotypes compared with a 4-dose 
PCV13 series. However, the OPA responses after 
the fourth dose were comparable for the two groups, 
and the clinical relevance of these lower antibody 
responses is not known. The single dose of PCV13 
among children aged ≥12 months who had received 
3 doses of PCV7 elicited IgG immune responses to 
the six additional serotypes that were comparable to 
those after a 3-dose infant PCV13 series (3).
Safety profile. The safety of PCV13 was assessed 
in 13 clinical trials in which 4,729 healthy infants and 
toddlers were administered at least 1 dose of PCV13 
and 2,760 children received at least 1 dose of PCV7, 
concomitantly with other routine pediatric vaccines. 
The most commonly reported (more than 20% of sub-
jects) solicited adverse reactions that occurred within 
7 days after each dose of PCV13 were injection-site 
reactions, fever, decreased appetite, irritability, and 
increased or decreased sleep (2). The incidence and 
severity of solicited local reactions at the injection 
site (pain/tenderness, erythema, and induration/
swelling) and solicited systemic reactions (irritability, 
drowsiness/increased sleep, decreased appetite, fever, 
and restless sleep/decreased sleep) were similar in the 
PCV13 and PCV7 groups. These data suggest that the 
safety profiles of PCV13 and PCV7 are comparable 
(2); CDC will conduct postlicensure monitoring for 
adverse events, and the manufacturer will conduct a 
Phase IV study.
Supportive data for safety outcomes were provided 
by a catch-up study among 354 children aged 7–71 
months who received at least 1 dose of PCV13. In 
addition, an open label study was conducted among 
284 healthy U.S. children aged 15–59 months who 
had previously received 3 or 4 doses of PCV7 (2). 
Among these children, the frequency and severity of 
solicited local reactions and systemic adverse reac-
tions after 1 dose of PCV13 were comparable to 
those among children receiving their fourth dose of 
PCV13 (2).
Indications and Guidance for Use
ACIP recommends PCV13 for all children aged 
2–59 months. ACIP also recommends PCV13 for 
children aged 60–71 months with underlying medical 
conditions that increase their risk for pneumococcal 
disease or complications (Table 1). 
No previous PCV7/PCV13 vaccination. The 
ACIP recommendation for routine vaccination with 
PCV13 and the immunization schedules for infants 
and toddlers through age 59 months who have not 
received any previous PCV7 or PCV13 doses are the 
same as those previously published for PCV7 (4,5). 
PCV13 is recommended as a 4-dose series at ages 2, 4, 
6, and 12–15 months. Infants receiving their first dose 
at age ≤6 months should receive 3 doses of PCV13 
at intervals of approximately 8 weeks (the minimum 
interval is 4 weeks). The fourth dose is recommended 
at age 12–15 months, and at least 8 weeks after the 
third dose (Table 2). 
Children aged 7–59 months who have not been 
vaccinated with PCV7 or PCV13 previously should 
receive 1 to 3 doses of PCV13, depending on their 
age at the time when vaccination begins and whether 
underlying medical conditions are present (Table 2). 
Children aged 24–71 months with chronic medical 
conditions that increase their risk for pneumococcal 
disease should receive 2 doses of PCV13. Interruption 
of the vaccination schedule does not require reinsti-
tution of the entire series or the addition of extra 
doses.
Incomplete PCV7/ PCV13 vaccination. Infants 
and children who have received 1 or more doses of 
PCV7 should complete the immunization series with 
PCV13 (Table 3). Children aged 12–23 months who 
have received 3 doses of PCV7 before age 12 months 
are recommended to receive 1 dose of PCV13, given 
at least 8 weeks after the last dose of PCV7. No addi-
tional PCV13 doses are recommended for children 
aged 12–23 months who received 2 or 3 doses of 
PCV7 before age 12 months and at least 1 dose of 
PCV13 at age ≥12 months.
Similar to the previous ACIP recommendation for 
use of PCV7 (6), 1 dose of PCV13 is recommended 
for all healthy children aged 24–59 months with any 
incomplete PCV schedule (PCV7 or PCV13). For 
children aged 24–71 months with underlying medical 
conditions who have received any incomplete sched-
ule of <3 doses of PCV (PCV7 or PCV13) before 
age 24 months, 2 doses of PCV13 are recommended. 
For children with underlying medical conditions who 
have received 3 doses of PCV (PCV7 or PCV13) a 
single dose of PCV13 is recommended through age 
71 months. The minimum interval between doses is 
8 weeks.
MMWR  Morbidity and Mortality Weekly Report
260 MMWR  /  March 12, 2010  /  Vol. 59  /  No. 9
TABLE 1. Underlying medical conditions that are indications for pneumococcal vaccination among children, by risk group — 
Advisory Committee on Immunization Practices (ACIP), United States, 2010
Risk group Condition





Children with functional or 
anatomic asplenia
Sickle cell disease and other hemoglobinopathies




Chronic renal failure and nephrotic syndrome
Diseases associated with treatment with immunosuppressive drugs or radiation therapy, including 
malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; or solid organ transplantation
Congenital immunodeficiency§ 
* Particularly cyanotic congenital heart disease and cardiac failure.
† Including asthma if treated with prolonged high-dose oral corticosteroids. 
§ Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic 
disorders (excluding chronic granulomatous disease).
TABLE 2. Recommended routine vaccination schedule for 13-valent pneumococcal conjugate vaccine (PCV13) among infants 
and children who have not received previous doses of 7-valent vaccine (PCV7) or PCV13, by age at first dose — Advisory 
Committee on Immunization Practices (ACIP), United States, 2010
Age at first dose (mos) Primary PCV13 series* PCV13 booster dose†
2–6 3 doses 1 dose at age 12–15 mos
7–11 2 doses 1 dose at age 12–15 mos
12–23 2 doses —
24–59 (Healthy children) 1 dose —
24–71 (Children with certain chronic diseases or 
immunocompromising conditions§)
2 doses —
* Minimum interval between doses is 8 weeks except for children vaccinated at age <12 months for whom minimum interval between doses 
is 4 weeks. Minimum age for administration of first dose is 6 weeks.
† Given at least 8 weeks after the previous dose.
§  For complete list of conditions, see Table 1.
TABLE 3. Recommended transition schedule from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent vaccine 
(PCV13) vaccination among infants and children, according to number of previous PCV7 doses received — Advisory 
Committee on Immunization Practices (ACIP), United States, 2010
Infant series Booster dose
Supplemental
PCV13 dose
2 mos 4 mos 6 mos ≥12 mos* 14–59 mos†
PCV7 PCV13 PCV13 PCV13 —
PCV7 PCV7 PCV13 PCV13 —
PCV7 PCV7 PCV7 PCV13 —
PCV7 PCV7 PCV7 PCV7 PCV13
* No additional PCV13 doses are indicated for children age 12–23 months who have received 2 or 3 doses of PCV before age 12 months 
and at least 1 dose of PCV13 at age ≥12 months.
† For children with underlying medical conditions (see Table 1), a single supplemental PCV13 dose is recommended through age 71 
months 
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Complete PCV7 vaccination. A single supple-
mental dose of PCV13 is recommended for all chil-
dren aged 14–59 months who have received 4 doses 
of PCV7 or another age-appropriate, complete PCV7 
schedule (Table 3). For children who have underlying 
medical conditions, a single supplemental PCV13 
dose is recommended through age 71 months. This 
includes children who have previously received the 
23-valent pneumococcal polysaccharide vaccine 
(PPSV23). PCV13 should be given at least 8 weeks 
after the last dose of PCV7 or PPSV23.
In addition, a single dose of PCV13 may be 
administered to children aged 6–18 years who are at 
increased risk for IPD because of sickle cell disease, 
human immunodeficiency virus (HIV) infection or 
other immunocompromising condition, cochlear 
implant, or cerebrospinal fluid leaks, regardless of 
whether they have previously received PCV7 or 
PPSV23. Routine use of PCV13 is not recommended 
for healthy children aged ≥5 years.
Precautions and Contraindications
Before administering PCV13, vaccination provid-
ers should consult the package insert for precautions, 
warnings, and contraindications. Vaccination with 
PCV13 is contraindicated among persons known to 
have severe allergic reaction (e.g., anaphylaxis) to any 
component of PCV13 or PCV7 or to any diphtheria 
toxoid-containing vaccine (2).
Transition from PCV7 to PCV13
When PCV13 is available in the vaccination 
provider’s office, unvaccinated children and children 
incompletely vaccinated with PCV7 should complete 
the immunization series with PCV13. If the only 
pneumococcal conjugate vaccine available in a pro-
vider’s office is PCV7, that vaccine should be provided 
to children and infants who are due for vaccination; 
these children should complete their series with 
PCV13 at subsequent visits. Children for whom the 
supplemental PCV13 dose is recommended should 
receive it at their next medical visit, at least 8 weeks 
after the last dose of PCV7. 
According to the manufacturer, supplies of PCV13 
should be adequate to allow providers to vaccinate 
children according to the routine immunization 
schedule and provide a supplemental dose as rec-
ommended. For private vaccine supplies, providers 
should contact Pfizer’s customer service department 
(telephone, 800-666-7248) with questions about 
purchasing quantities of PCV13 or returning PCV7 
for credit. For public vaccine supplies, including 
Vaccines for Children Program vaccine, providers 
should contact their state/local immunization pro-
gram to determine when PCV13 will become available 
for ordering in their jurisdiction and what to do with 
unused supplies of PCV7. 
The PCV13 Vaccine Information Statement is 
available at http://www.cdc.gov/vaccines/pubs/vis/
default.htm. Details about the routine pneumococ-
cal conjugate vaccination schedule are available at 
http://www.cdc.gov/vaccines/recs/schedules/default.
htm#child. Adverse events after receipt of any vac-
cine should be reported to the Vaccine Adverse Event 
Reporting System at http://vaers.hhs.gov. 
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On April 12, 2006, Massachusetts enacted legisla-
tion to provide nearly universal health-care coverage 
to state residents (1). Beginning in mid-2006, various 
components of the law were launched in approximate 
6-month intervals. One key component required all 
Massachusetts residents to purchase health insurance 
by July 1, 2007, either through private insurers or 
Commonwealth Care, a new state-subsidized health 
insurance program. To analyze the short-term effects 
of this legislation on health insurance coverage, the 
Massachusetts Department of Public Health (MDPH) 
reviewed data from the state’s Behavioral Risk Factor 
Surveillance System (BRFSS) survey. An 18-month 
pre-law period and an 18-month post-law period were 
identified for comparison; the 12-month transition 
period from July 1, 2006, to June 30, 2007, during 
which the law took effect, was not included in the 
analysis. BRFSS data from the pre-law and post-law 
periods were compared to evaluate effects on the 
overall adult population aged 18–64 years and on 
various subpopulations. This report summarizes the 
results of those comparisons, which determined that 
health insurance coverage statewide increased by 
5.5%, from 91.3% in the pre-law period to 96.3% 
in the post-law period, and that coverage increased 
14.2% among Hispanics, from 77.9% to 89.0%. 
Despite the limitations inherent in this analysis, the 
increases in coverage likely are attributable to the new 
law. MDPH is using these results to target outreach 
more precisely to increase health insurance enrollment 
and health-care access among state residents.
BRFSS is a state-based, random-digit–dialed 
telephone survey of the noninstitutionalized U.S. 
civilian population aged ≥18 years and is conducted by 
state health departments in collaboration with CDC 
(2).* The overall sample size for the Massachusetts 
BRFSS increased from 8,906 respondents in 2005 
to 20,559 respondents in 2008 because of increased 
participation by state public health programs. The 
response rate† for the Massachusetts BRFSS ranged 
from 38% in 2005 to 48% in 2008, based on Council 
of American Survey and Research Organizations 
(CASRO) guidelines. The cooperation rate was 81% 
in 2008. 
To gather information on health insurance, begin-
ning in 1998 MDPH added three supplementary 
questions to the Massachusetts BRFSS survey. One 
new question asked all respondents who had health 
insurance to identify the type of coverage they used 
to pay for most of their medical care. Response 
options included various private, public, and other 
insurance plans;§ Commonwealth Care¶ was added 
as a public plan response option in 2008. Beginning 
in September 2007 and continuing through 2008, 
the survey also included a set of questions tracking 
awareness of health-care reform and asking whether 
the respondent obtained health-care coverage because 
of the recent changes in Massachusetts law (3). 
To analyze the effect of the law, two 18-month 
periods were chosen: January 1, 2005–June 30, 2006 
(the pre-law period) and July 1, 2007–December 31, 
2008 (the post-law period). The 12-month transition 
period from July 1, 2006, to June 30, 2007, during 
which the law took effect, was not included in the 
analysis. Health indicators for various population 
subgroups were analyzed, comparing the pre-law 
and post-law periods. Since 1994, the Massachusetts 
BRFSS has oversampled cities with highly diversified 
populations, including large Hispanic communities. 
Data for adults aged 18–64 years were analyzed; 
Short-Term Effects of Health-Care Coverage Legislation — 
Massachusetts, 2008
* BRFSS survey information is available at http://www.cdc.gov/
BRFSS/technical_infodata/surveydata/2008.htm.
† The response rate is the percentage of persons who completed 
interviews among all eligible persons, including those who were 
not successfully contacted. The cooperation rate is the percentage of 
persons who completed interviews among all eligible persons who 
were contacted. 
§ Type of insurance was classified as 1) private insurance: coverage 
through an employer, someone else’s employer, or a plan purchased 
by the person covered; 2) public insurance: Medicare, Medicaid, 
MassHealth, CommonHealth MassHealth, health maintenance 
organizations offered through Neighborhood Health Plan, Fallon 
Community Health Plan, BMC HealthNet or Network Health, 
Commonwealth Care, the military, CHAMPUS, TriCare, Veterans 
Administration (VA), CHAMP-VA, Indian Health Service, or the 
Alaska Native Health Service; or 3) other insurance: some other 
source of health insurance, such as a self-directed plan or student 
health insurance. 
¶ A key element of the health-care legislation in Massachusetts was 
creation of the Commonwealth Health Insurance Connector, the 
agency responsible for connecting residents to either Commonwealth 
Care, a subsidized program for certain adults who have not been 
offered employer-sponsored insurance, or Commonwealth Choice, 
an unsubsidized offering of six private health plans available 
through the Health Connector to individuals, families, and certain 
employers.
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data for adults aged 18–34 years also were analyzed 
separately to more closely examine this traditionally 
underinsured age group. The statistical significance 
(p<0.05) of differences between health indicators 
in the pre-law and post- law periods was estimated 
using the Wald chi-square test. Variability of point 
estimates of weighted** proportions was indicated 
by 95% confidence intervals. 
The percentage of respondents who reported 
having health insurance rose 5.5%, from 91.3% in 
the pre-law period to 96.3% in the post-law period 
(Table 1). Among major subpopulations, the largest 
increases were observed among Hispanics (14.2%), 
persons with less than a high school diploma (12.0%), 
and persons with annual household incomes <$25,000 
(11.9%). Nonetheless, in the post-law period, these 
same three subpopulations continued to have the low-
est percentages of health insurance coverage: 89.0% 
for Hispanics, 88.6% for persons with less than a high 
school diploma, and 89.0% for persons with annual 
household incomes <$25,000.
By 2008, approximately 8% of publicly insured 
Massachusetts residents were obtaining their health 
insurance through the new public Commonwealth 
Care program. The percentage of insured residents 
with public health insurance (including those aged 
18–64 years who were eligible for Medicare) increased 
29.7%, from 14.8% in the pre-law period to 19.2% 
in the post-law period (Table 1). The percentage of 
insured residents with private insurance decreased 
3.2%, from 80.8% to 78.2%, and the percentage 
of insured residents with other types of insurance 
(e.g., a self-directed plan or student health insurance) 
decreased 40.9%, from 4.4% to 2.6% (Table 1).
The overall percentage of respondents who reported 
having a personal health-care provider increased sig-
nificantly, from 86.1% in the pre-law period to 87.7% 
in the post-law period (Table 2). The largest reported 
increases occurred among Hispanic respondents who 
answered the survey in Spanish (30.3% increase) and 
among Hispanics overall (17.0% increase). 
The percentage of respondents who reported 
having a routine checkup within the past year also 
increased significantly, from 71.9% in the pre-law 
period to 74.1% in the post-law period (Table 3). The 
largest reported increases occurred among Hispanic 
respondents who answered the survey in Spanish 
(19.9% increase) and among Hispanics overall 
(14.1% increase). The percentage of men reporting 
a routine checkup increased 5.1%, from 66.4% to 
69.8%, but the percentage of women reporting a 
routine checkup did not change significantly. The 
percentage of respondents with chronic conditions 
who reported having a personal health-care provider 
or having had an annual checkup also did not change 
significantly after enactment of the health-care cover-
age law. 
Reported by
L Tinsley, MPH, B Andrews, MPH, H Hawk, PhD, B Cohen, 
PhD, Bur of Health Information, Statistics, Research, and 
Evaluation, Massachusetts Dept of Public Health. 
Editorial Note
The results of this analysis indicate that the esti-
mated percentage of Massachusetts residents covered 
by health insurance increased significantly after pas-
sage of health-care coverage legislation. A wider com-
parison, between 2005 BRFSS state survey results and 
2008 results, indicated that health insurance coverage 
increased from 89% to 97% among all state residents 
(including children and adults aged ≥65 years); the 
increase included an estimated 300,000 newly insured 
persons aged 18–64 years (3). After implementation 
of the health-care coverage law, the proportion of 
respondents who said they lacked health insurance 
was approximately cut in half, and 8% of publicly 
insured respondents were obtaining health insur-
ance through the state’s new Commonwealth Care 
program. The effects observed likely are attributable 
to the new law; although, because of limitations inher-
ent in such studies, a causal link cannot be proven. 
Increases in health insurance coverage can result from 
multiple factors, such as a higher employment rate, 
reduction in health insurance premiums, or expansion 
of existing public health insurance programs. During 
1996–1999, Massachusetts observed an increase in the 
percentage of persons with health insurance (3) after 
the state expanded Medicaid eligibility; as a result, an 
additional 124,000 Massachusetts residents obtained 
insurance coverage (4). 
In this analysis, the observed increases in the per-
centage of insured among traditionally underserved 
subpopulations (e.g., Hispanics, persons with less 
than a high school diploma, and persons with annual 
household incomes <$25,000) serve to strengthen the 
hypothesis that the increases in insurance coverage are 
 ** Data were weighted to the total Massachusetts population. The 
BRFSS weighting methodology is available at http://www.cdc.gov/
brfss/technical_infodata/surveydata/2008/overview_08.rtf.
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TABLE 1. Number and percentage of adults aged 18–64 years who reported having health insurance,* before and after enactment of health-care 
coverage law, by selected characteristics — Behavioral Risk Factor Surveillance System, Massachusetts, 2005–2008
Characteristic
Pre-law 
(January 1, 2005–June 30, 2006†)
Post-law 
(July 1, 2007–December 31, 2008†)
% change after 
enactment of law p value††No.§ %¶ (95% CI**) No. % (95% CI)
Statewide 11,483 91.3 (90.5–92.1) 22,749 96.3 (95.9–96.8) 5.5 <0.001
Sex 
Male 4,483 89.4 (88.0–90.8) 8,483 95.0 (94.2–95.9) 6.3 <0.001
Female 7,000 93.2 (92.2–94.1) 14,266 97.6 (97.2–98.0) 4.7 <0.001
Sex (18–34 yrs age group only)
Male 956 82.9 (79.6–86.3) 1,574 91.7 (89.7–93.8) 10.6 <0.001
Female 1,664 91.0 (89.1–93.0) 2,646 96.7 (95.8–97.6) 6.3 <0.001
Age group (yrs)
18–34 2,620 87.1 (85.2–89.0) 4,220 94.3 (93.1–95.4) 8.3 <0.001
35–44 3,039 93.5 (92.3–94.7) 5,340 97.2 (96.4–97.9) 4.0 <0.001
45–54 3,147 93.6 (92.4–94.8) 6,716 97.4 (96.8–97.9) 4.1 <0.001
55–64 2,677 94.1 (92.8–95.3) 6,473 97.5 (96.7–98.3) 3.6 <0.001
Race/Ethnicity
White, non-Hispanic 9,090 93.0 (92.2–93.9) 17,930 97.3 (96.8–97.7) 4.6 <0.001
Black, non-Hispanic 564 88.2 (84.0–92.3) 1,281 92.7 (89.9–95.5) 5.1 0.068
Hispanic 1,255 77.9 (73.7–82.1) 2,438 89.0 (86.4–91.6) 14.2 <0.001
Asian 245 90.5 (85.0–96.0) 509 98.4 (97.3–99.5) 8.7 0.001
Language of response among Hispanics
English 758 84.6 (80.0–89.1) 1,323 93.3 (90.8–95.8) 10.3 0.001
Spanish 450 69.1 (61.2–77.0) 1,070 81.8 (76.1–87.5) 18.4 0.01
Education
Less than high school diploma or GED§§ 1,002 79.1 (74.3–84.0) 1,859 88.6 (85.3–92.0) 12.0 0.002
At least high school diploma or GED 10,456 92.2 (91.4–93.0) 20,815 96.8 (96.4–97.3) 5.0 <0.001
Annual household income
<$25,000 2,239 79.5 (76.7–82.3) 4,437 89.0 (87.1–90.9) 11.9 <0.001
$25,000–$74,999 4,255 91.0 (89.6–92.4) 7,864 96.2 (95.4–97.0) 5.7 <0.001
≥$75,000 3,562 97.4 (96.6–98.3) 8,099 99.4 (99.2–99.7) 2.1 <0.001
Chronic health condition
Fair or poor health¶¶ 1,660 85.3 (82.3–88.2) 3,337 92.8 (90.7–94.8) 8.8 <0.001
Disabled >1 yr*** 1,162 91.1 (88.5–93.7) 3,504 97.1 (96.1–98.0) 6.6 <0.001
Diabetic††† 764 92.4 (89.5–95.4) 1,759 97.9 (97.0–98.9) 6.0 <0.001
Current asthma§§§ 1,304 93.0 (90.7–95.3) 2,527 96.1 (94.3–98.0) 3.3 0.047
Insurance type among persons insured
Private¶¶¶ 8,077 80.8 (79.6–81.9) 15,931 78.2 (77.2–79.1) -3.2 <0.001
Public**** 1,981 14.8 (13.8–15.9) 5,357 19.2 (18.4–20.1) 29.7 <0.001
Other†††† 439 4.4 (3.8–5.0) 565 2.6 (2.3–3.0) -40.9 <0.001
 * Determined by a “yes” response to the question, “Do you have any kind of health-care coverage, including health insurance, prepaid plans such as health main-
tenance organizations, or government plans such as Medicare?” in conjunction with response provided to the subsequent question, “What type of health-care 
coverage do you use to pay for most of your medical care?”
 † The 12-month transition period from July 1, 2006, to June 30, 2007, during which the law took effect, was not included in the analysis.
 § Subgroups might not sum to survey total because of missing responses within each subgroup.
 ¶ Weighted percentages.
 ** Confidence interval.
 †† p values were calculated using the Wald chi-square test of the difference between each period.
 §§ General Educational Development certificate.
 ¶¶ Responded “fair” or “poor” to the question, “Would you say that in general your health is excellent, very good, good, fair, or poor?”
 *** Responded “yes” to the question, “A disability can be physical, mental, emotional, or communication-related. Would you describe yourself as having a disability of any 
kind?” plus indicated >1 year when asked, “For how long have your activities been limited because of your major impairment, health problem, or disability?”
 ††† Responded “yes” to the question, “Have you ever been told by a doctor that you have diabetes?”
 §§§ Responded “yes” to both of these questions: “Have you ever been told by a doctor, nurse, or other health professional that you had asthma?” and “Do you still 
have asthma?”
 ¶¶¶ Defined as coverage through an employer, someone else’s employer, or a plan purchased by the person covered.
 **** Defined as coverage through Medicare, Medicaid, MassHealth, CommonHealth MassHealth, health maintenance organizations offered through Neighborhood 
Health Plan, Fallon Community Health Plan, BMC HealthNet or Network Health, Commonwealth Care, the military, CHAMPUS, TriCare, Veterans Administration 
(VA), CHAMP-VA, Indian Health Service, or the Alaska Native Health Service.
 †††† Defined as some other source of health insurance such as a self-directed plan or student health insurance.
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attributable to the health-care coverage law, because 
implementation of heavily subsidized health insurance 
programs likely would affect these subpopulations first. 
Data from similar surveys in Massachusetts support 
this same hypothesis (5–7). For example, reports from 
the Massachusetts Division of Health Care Finance 
and Policy, which were focused on insurance status 
specifically, found that from fall 2006 to fall 2008, the 
number of uninsured working-age adults was reduced 
by nearly 70%. Most of the gains in insurance cover-
age were concentrated among lower-income adults 
(7). In contrast, according to U.S. Census data, from 
2007 to 2008, the overall proportion of U.S. adults 
with health insurance declined (8).
The largest increases in insurance coverage were 
among Hispanic respondents overall and Hispanic 
respondents who answered the survey in Spanish. 
Traditionally, a larger proportion of Hispanics in 
TABLE 2. Number and percentage of adults aged 18–64 years who reported having a personal doctor or health-care provider,* before and after 
enactment of health-care coverage law, by selected characteristics — Behavioral Risk Factor Surveillance System, Massachusetts, 2005–2008
Characteristic
Pre-law 
(January 1, 2005–June 30, 2006†)
Post-law 
(July 1, 2007–December 31, 2008†)
% change after 
enactment of law p value††No.§ %¶ (95% CI**) No. % (95% CI)
Statewide 11,478 86.1 (85.0–87.1) 22,738 87.7 (86.9–88.5) 1.9 0.014
Sex 
Male 4,482 82.3 (80.7–84.0) 8,486 84.1 (82.8–85.5) 2.2 0.104
Female 6,996 89.6 (88.4–90.8) 14,252 91.1 (90.2–92.0) 1.7 0.041
Sex (18–34 yrs age group only)
Male 958 71.6 (67.7–75.5) 1,576 72.0 (68.7–75.4) 0.6 0.870
Female 1,663 82.1 (79.3–84.9) 2,643 84.7 (82.4–87.1) 3.2 0.154
Age group (yrs)
18–34 2,621 77.0 (74.6–79.4) 4,219 78.5 (76.4–80.5) 1.9 0.360
35–44 3,037 88.6 (87.1–90.2) 5,332 89.7 (88.5–90.9) 1.2 0.261
45–54 3,146 91.9 (90.6–93.2) 6,717 92.8 (91.8–93.7) 1.0 0.298
55–64 2,674 94.0 (92.8–95.2) 6,470 94.6 (93.5–95.7) 0.6 0.483
Race/Ethnicity
White, non-Hispanic 9,084 89.0 (88.0–90.0) 17,929 90.2 (89.3–91.0) 1.3 0.083
Black, non-Hispanic 565 84.9 (79.8–89.9) 1,279 80.1 (75.6–84.6) -5.7 0.183
Hispanic 1,258 63.5 (58.8–68.3) 2,432 74.3 (71.0–77.7) 17.0 <0.001
Asian 244 76.9 (68.9–84.8) 507 79.8 (73.8–85.9) 3.8 0.556
Language of response among Hispanics
English 758 74.8 (69.7–79.9) 1,320 81.7 (77.8–85.5) 9.2 0.033
Spanish 453 47.2 (39.6–54.9) 1,066 61.5 (55.5–67.5) 30.3 0.004
Education
Less than high school diploma or GED§§ 1,004 68.9 (63.5–74.2) 1,862 72.7 (68.2–77.2) 5.5 0.278
At least high school diploma or GED 10,457 87.4 (86.4–88.4) 20,802 88.7 (87.9–89.5) 1.5 0.049
Annual household income
<$25,000 2,236 74.7 (71.6–77.8) 4,436 76.2 (73.6–78.9) 2.0 0.456
$25,000–$74,999 4,247 86.4 (84.8–88.0) 7,854 87.6 (86.2–89.0) 1.4 0.253
≥$75,000 3,561 92.5 (91.2–93.9) 8,096 92.6 (91.7–93.5) 0.1 0.948
Chronic health condition
Fair or poor health¶¶ 1,659 85.9 (82.9–88.9) 3,336 84.1 (81.3–86.9) -2.1 0.395
Disabled >1 yr*** 1,162 87.7 (84.3–91.2) 3,506 89.9 (87.9–91.9) 2.5 0.262
Diabetic††† 764 94.6 (91.9–97.3) 1,756 96.5 (95.1–97.8) 2.0 0.178
Current asthma§§§ 1,300 91.7 (89.1–94.4) 2,524 88.2 (85.3–91.0) -3.8 0.075
 * Determined by “yes” response to the question, “Do you have one person you think of as your personal doctor or health-care provider?”
 † The 12-month transition period from July 1, 2006, to June 30, 2007, during which the law took effect, was not included in the analysis.
 § Subgroups might not sum to survey total because of missing responses within each subgroup.
 ¶ Weighted percentages.
 ** Confidence interval.
 †† p values were calculated using the Wald chi-square test of the difference between each period.
 §§ General Educational Development certificate.
 ¶¶ Responded “fair” or “poor” to the question, “Would you say that in general your health is excellent, very good, good, fair, or poor?”
 *** Responded “yes” to the question, “A disability can be physical, mental, emotional, or communication-related. Would you describe yourself as having a disability of 
any kind?” plus indicated >1 year when asked, “For how long have your activities been limited because of your major impairment, health problem, or disability?”
 ††† Responded “yes” to the question, “Have you ever been told by a doctor that you have diabetes?”
 §§§ Responded “yes” to both of these questions: “Have you ever been told by a doctor, nurse, or other health professional that you had asthma?” and “Do you still have asthma?”
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Massachusetts have lacked access to health care, 
compared with other racial/ethnic populations (9,10). 
The results showed an 18.4% increase for persons 
responding in Spanish and a 14.2% increase for 
Hispanics overall. However, despite these increases, 
Hispanics continued to have the lowest health insur-
ance coverage and the lowest percentage of persons 
with a personal health-care provider than any other 
subpopulation. The percentage of younger adults, 
whites, blacks, and persons with chronic diseases who 
reported having a personal health-care provider did 
not change significantly. One reason might be that 
more time is needed for the effects of improved health-
care access to be realized in these groups. Another 
reason might be that health-care providers are not 
equally accessible for certain groups or in certain areas 
TABLE 3. Number and percentage of adults aged 18–64 years who reported visiting a doctor within the preceding 12 months for a routine checkup,* 




(January 1, 2005–June 30, 2006†)
Post-law 
(July 1, 2007–December 31, 2008†)
% change after 
enactment of law p value††No.§ %¶ (95% CI**) No. % (95% CI)
Statewide 11,401 71.9 (70.7–73.2) 22,617 74.1 (73.2–75.1) 3.1 0.006
Sex 
Male 4,445 66.4 (64.4–68.4) 8,431 69.8 (68.2–71.3) 5.1 0.009
Female 6,956 77.2 (75.7–78.7) 14,186 78.3 (77.2–79.4) 1.4 0.249
Sex (18–34 age yrs group only)
Male 943 61.8 (57.6–66.0) 1,560 64.7 (61.2–68.3) 4.7 0.294
Female 1,656 75.4 (72.1–78.7) 2,618 75.5 (72.8–78.2) 0.1 0.974
Age group (yrs)
18–34 2,599 68.8 (66.2–71.5) 4,178 70.2 (68.0–72.4) 2.0 0.438
35–44 3,026 68.1 (65.9–70.3) 5,311 70.7 (68.9–72.5) 3.8 0.069
45–54 3,122 73.4 (71.2–75.6) 6,686 76.2 (74.7–77.7) 3.8 0.038
55–64 2,654 82.5 (80.5–84.5) 6,442 83.7 (82.3–85.1) 1.5 0.326
Race/Ethnicity
White, non-Hispanic 9,030 71.8 (70.5–73.2) 17,842 73.5 (72.4–74.5) 2.4 0.067
Black, non-Hispanic 562 82.2 (77.9–86.5) 1,276 78.1 (73.6–82.6) -5.0 0.201
Hispanic 1,240 71.1 (66.4–75.8) 2,412 81.1 (78.1–84.1) 14.1 <0.001
Asian 243 61.8 (53.0–70.5) 504 67.8 (61.6–74.0) 9.7 0.269
Language of response among Hispanics
English 752 75.0 (69.3–80.6) 1,308 80.6 (76.6 – 84.5) 7.5 0.103
Spanish 442 69.3 (61.3–77.2) 1,058 83.1 (78.6 – 87.6) 19.9 0.002
Education
Less than high school diploma or GED§§ 986 74.3 (69.3–79.4) 1,844 73.9 (69.4–78.5) -0.5 0.901
At least high school diploma or GED 10,398 71.7 (70.4–73.0) 20,702 74.1 (73.2–75.1) 3.3 0.003
Annual household income
<$25,000 2,216 71.3 (68.2–74.5) 4,410 74.1 (71.6–76.5) 3.9 0.176
$25,000–$74,999 4,223 71.3 (69.2–73.4) 7,823 74.4 (72.8–76.0) 4.3 0.021
≥$75,000 3,551 72.5 (70.5–74.5) 8,067 74.3 (72.9–75.7) 2.5 0.161
Chronic health condition
Fair or poor health¶¶ 1,641 77.5 (74.0–81.1) 3,309 79.5 (76.5–82.4) 2.6 0.410
Disabled >1 yr*** 1,156 77.9 (74.2–81.7) 3,481 79.3 (76.9–81.7) 1.8 0.533
Diabetic††† 761 89.1 (85.5–92.7) 1,745 91.8 (89.9–93.8) 3.0 0.165
Current asthma§§§ 1,293 79.8 (76.4–83.2) 2,507 76.6 (73.6–79.7) -4.0 0.177
 * Determined by a response of “within the past year (any time less than 12 months ago)” to the question, “About how long has it been since you last visited a  doctor 
for a routine checkup? A routine checkup is a general physical exam, not an exam for a specific injury, illness, or condition.”
 † The 12-month transition period from July 1, 2006, to June 30, 2007, during which the law took effect, was not included in the analysis.
 § Subgroups might not sum to survey total because of missing responses within each subgroup.
 ¶ Weighted percentages.
 ** Confidence interval.
 †† p values were calculated using the Wald chi-square test of the difference between each period.
 §§ General Educational Development certificate.
 ¶¶ Responded “fair” or “poor” to the question, “Would you say that in general your health is excellent, very good, good, fair, or poor?”
 *** Responded “yes” to the question, “A disability can be physical, mental, emotional, or communication-related. Would you describe yourself as having a disability of any 
kind?” plus indicated >1 year when asked, “For how long have your activities been limited because of your major impairment, health problem, or disability?”
 ††† Responded “yes” to the question, “Have you ever been told by a doctor that you have diabetes?”
 §§§ Responded “yes” to both of these questions: “Have you ever been told by a doctor, nurse, or other health professional that you had asthma?” and “Do you still have asthma?” 
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of the state. Although the cost of a doctor visit might 
also be a factor, 2008 BRFSS data have shown that 
only 6% of all respondents reported that they were 
unable to visit a doctor during the past year because 
of cost, compared with 8% in 2006 (9). 
In addition to an increase in the percentage of per-
sons with health insurance, the findings in this analysis 
indicate changes in the proportion of plans that were 
private, public, or other (e.g., a self-directed plan or 
student health insurance) in Massachusetts. Those 
proportions changed from 80.8% private, 14.8% 
public, and 4.4% other before the law was enacted to 
78.2%, 19.2%, and 2.6%, respectively. These changes 
were similar to U.S. Census data, which found that 
the proportion of adults with private health insurance 
declined from 2007 to 2008, while the proportion of 
publicly insured adults increased (8).
In addition to the limitations on establishing cau-
sality, the findings in this report are subject to at least 
three other limitations. First, BRFSS only samples 
households with landline telephones. Minorities, 
persons with lower socioeconomic status, and younger 
adults typically have lower landline telephone cover-
age and might be underrepresented in this report. 
However, poststratification weighting might correct 
some bias resulting from lack of landline telephones. 
Second, depending on when the survey was admin-
istered, some responses might pertain to health-care 
activities (e.g., having a personal-care provider in the 
past year) that actually occurred during the 12-month 
transition period. Finally, BRFSS data are based on 
self-report and might be subject to error (e.g., under-
reporting of chronic conditions). 
The findings in this report and others (10) can 
help local health departments in areas with large 
underserved populations assess local public health 
needs, enhance cultural competency, engage hospi-
tals in community primary-care efforts, and address 
the availability of health-care providers. MDPH is 
targeting outreach more precisely to increase health 
insurance enrollment and health-care access among 
state residents.
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What is already known on this topic? 
Health-care coverage legislation in Massachusetts, 
enacted in 2006, was intended to extend affordable 
health insurance, resulting in increased health-care 
access and use. 
What is added by this report? 
Health-care coverage overall in Massachusetts 
increased from 91.3% to 96.3% after the law took 
effect, with the largest increase (14.2%) observed 
among Hispanics, although Hispanics continued to 
have the lowest percentage of health-care coverage 
(89.0%) among racial/ethnic groups.
What are the implications for public health practice?
Implementation of state-endorsed, low-cost, alterna-
tive health-care coverage appears to have contrib-
uted to an increase in the percentage of residents 
with health insurance, particularly in populations with 
the lowest health-care coverage; however, targeted 
efforts will be needed to reach these historically 
underserved populations.
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Afghanistan, Pakistan, India, and Nigeria are 
the four remaining countries where indigenous 
wild poliovirus (WPV) transmission has never been 
interrupted (1). This report updates previous reports 
(1,2) and describes polio eradication activities in 
Afghanistan and Pakistan during January–December 
2009 and proposed activities in 2010 to address 
challenges. During 2009, both countries continued 
to conduct coordinated supplemental immuniza-
tion activities (SIAs) and used multiple strategies to 
reach previously unreached children. These strate-
gies included 1) use of short interval additional dose 
(SIAD) SIAs to administer a dose of oral poliovirus 
vaccine (OPV) within 1–2 weeks after a prior dose 
during negotiated periods of security; 2) systematic 
engagement of local leaders; 3) negotiations with 
conflict parties; and 4) increased engagement of non-
governmental organizations delivering basic health 
services. However, security problems continued to 
limit access by vaccination teams to large numbers 
of children. In Afghanistan, poliovirus transmission 
during 2009 predominantly occurred in 12 high-
risk districts in the conflict-affected South Region; 
38 WPV cases were confirmed in 2009, compared 
with 31 in 2008. In Pakistan, 89 WPV cases were 
confirmed in 2009, compared with 118 in 2008, but 
transmission persisted both in security-compromised 
areas and in accessible areas, where managerial and 
operational problems continued to affect immuni-
zation coverage. Continued efforts to enhance safe 
access of vaccination teams in insecure areas will be 
required for further progress toward interruption of 
WPV transmission in Afghanistan and Pakistan. In 
addition, substantial improvements in subnational 
accountability and oversight are needed to improve 
immunization activities in Pakistan.
Immunization Activities 
Reported routine vaccination coverage of infants 
with 3 OPV doses (OPV3) in 2009 was 85% nation-
ally in Afghanistan and 81% in Pakistan (3). However, 
acute flaccid paralysis (AFP) surveillance data* suggest 
that actual routine OPV3 coverage was much lower 
nationally and varied widely by subnational level in 
both countries. Based on 2009 AFP surveillance data, 
routine OPV3 coverage among children aged 6–23 
months with nonpolio AFP was 63% nationally in 
Afghanistan (13% in the South Region and 76% in 
the rest of the country) and 61% nationally in Pakistan 
(69% in Punjab Province, 50% in Northwest Frontier 
Province [NWFP] and the Federally Administered 
Tribal Areas [FATA], 52% in Sindh Province, and 
23% in Balochistan Province). 
During 2009, large-scale house-to-house SIAs† 
targeting children aged <5 years using different for-
mulations of OPV, depending on the epidemiologic 
situation, continued in both countries (Table 1). 
OPV formulations included trivalent (tOPV), mon-
ovalent type 1 (mOPV1) and type 3 (mOPV3), or 
OPV bivalent types 1 and 3 (bOPV).§ Afghanistan 
conducted six national immunization days (NIDs); 
four subnational immunization days (SNIDs) in the 
East, Southeast, and South regions along the border 
with Pakistan, three of which targeted nearly 50% 
of the national population of children aged <5 years; 
and four smaller-scale SIAD¶ SIAs after a preceding 
larger SIA, targeting children in conflict-affected 
areas of the South Region. Pakistan conducted six 
NIDs; four SNIDs in the main WPV transmission 
areas of NWFP/FATA, southern Punjab, and Sindh 
(including Karachi city), targeting 40%–50% of the 
national population aged <5 years; and four SIAD 
SIAs in conflict-affected areas of NWFP/FATA. 
These included two SIAD SIAs in Swat Valley, tar-
geting >370,000 children aged <5 years, conducted 
after 1 year of civil conflict that prevented any polio 
vaccination.
Progress Toward Poliomyelitis Eradication — 
Afghanistan and Pakistan, 2009
* Vaccination histories of children aged 6–23 months with AFP who 
do not test WPV positive are used to estimate OPV coverage of the 
overall target population and to verify national reported routine 
vaccination coverage estimates.
† Mass campaigns conducted for a brief period (days to weeks) in 
which 1 dose of OPV is administered to all children aged <5 years, 
regardless of vaccination history. Campaigns can be conducted 
nationally or in portions of the country.
§ The first large-scale use of bOPV in the world occurred during the 
December 2009 SIA in Afghanistan.
¶ SIADs are used during negotiated periods of security to vaccinate 
children in otherwise inaccessible areas in which an mOPV dose is 
administered within 1–2 weeks of the previous dose.
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In 2009, as in past years, certain vaccination 
campaigns were unable to reach children aged <5 
years living in areas inaccessible** because of security 
problems. During 2009, the estimated percentage of 
children aged <5 years who were living in inaccessible 
areas in the South Region of Afghanistan ranged 
from >20% during SIAs conducted in January and 
March to 5% during the July and September SIAs. 
In Pakistan, the percentage of children aged <5 years 
who were living in SIA-inaccessible areas of NWFP 
increased from 10% in January to 20% in May and 
July, and then decreased to <5% in October and 
November. However, in FATA itself, the estimated 
percentage of children aged <5 years living in inac-
cessible areas increased from 15% in January to 30% 
by November. 
AFP Surveillance 
In 2009, AFP surveillance performance indica-
tors remained high in both countries, including in 
areas with ongoing WPV transmission.†† The annual 
national nonpolio AFP rate (per 100,000 population 
aged <15 years) was 8.5 in Afghanistan (range among 
the eight regions: 6.7–12.0) and 6.1 in Pakistan (range 
among the six provinces/territories: 2.9–9.2). The 
percentage of nonpolio AFP cases for which adequate 
specimens were collected was 93% in Afghanistan 
(range: 81%–97%) and 90% in Pakistan (range: 
83%–96%) (Table 2).
TABLE 1. Type of supplementary immunization activity (SIA) conducted and oral poliovirus vaccine (OPV) product used, by 
month — Afghanistan and Pakistan, 2009*
Country/Area
Month
Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
Type of SIA† and OPV§ product used
Afghanistan NID SNID NID SNID NID SNID NID SNID¶ NID NID SNID
Badakhshan T — T — T — T — — T T —
Northeast T — T — T — T — — T T —
North T — T — T — T — — T T —
Central T — T — T M1 T — — T T —
West
All others T — T — T — T — M1 T T —
Farah Province T M1 T M1 T M1 T — M1 T T B
East T M3 T M1 T M1 T — M3 T T B
Southeast T M3 T M1 T M1 T — M1 T T B
South T M1 T M1 T M1 T — M3 T T B
Pakistan NID NID SNID¶ NID SNID¶ NID SNID¶ NID NID SNID¶
FANA, AJK, and ICT** T — T — T — T — — T T —
NWFP and FATA†† T — T T,M1 T M1 T M1,M3 — T T M1
Punjab
Northern T,M1 — T M1 T M1 T M3 — T T M1
Southern T — T M1 T M1 T M1 — T T M1
Balochistan T — T M1 T M1 T M1 — T T M1
Sindh
North T — T M1 T M1 T M1,M3 — T T M1
Central and Karachi M3 — T M1 T M1 T M1,M3 — T T —
 * Data as of February 2, 2010. 
 † SIA type: NID = National immunization day, SNID = Subnational immunization day.
 § OPV product: T = trivalent OPV; B = bivalent OPV, types 1 and 3; M1 = monovalent OPV, type 1; M3 = monovalent OPV, type 3.
 ¶ SNIDs conducted in selected districts of each province or area.
 ** Azad, Jammu, Kashmir (AJK), the Federally Administered Northern Areas (FANA), and Islamabad Capital Territory (ICT).
 †† Northwest Frontier Province (NWFP), including the Federally Administrated Tribal Areas (FATA).
 ** Areas considered too dangerous by the World Health Organization 
(WHO) and the local government to conduct an SIA.
 †† The quality of AFP surveillance is monitored by three performance 
indicators: 1) detection rate of AFP cases not caused by WPV; 2) 
the proportion of AFP cases with adequate stool specimens; and 3) 
the proportion of stool specimens processed in a WHO-accredited 
laboratory. Current WHO operational targets for countries with 
endemic polio transmission are a nonpolio AFP detection rate 
of at least two cases per 100,000 population aged <15 years and 
adequate stool-specimen collection from >80% of AFP cases, in 
which two specimens are collected at least 24 hours apart, both 
within 14 days of paralysis onset, and shipped on ice or frozen packs 
to a WHO-accredited laboratory, arriving in good condition.
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The polio laboratory at the National Institutes 
of Health (NIH) in Islamabad provides laboratory 
support for AFP surveillance in both countries, 
including genomic sequencing of poliovirus isolates. 
During 2009, the NIH laboratory processed 3,779 
stool specimens from Afghanistan and 11,501 stool 
specimens from Pakistan. In 2009, to supplement 
AFP surveillance, Pakistan initiated weekly sewage 
sample collection in Lahore, Punjab Province, and 
Karachi, Sindh Province, to test for polioviruses. 
WPV Incidence
In Afghanistan, 38 WPV cases (15 WPV1 and 23 
WPV3) were reported during 2009, compared with 
31 WPV cases (25 WPV1 and six WPV3) in 2008 
(Figure, Table 2). During 2009, a total of 26 (68%) 
WPV cases were among children aged <36 months; 
nine (24%) had received no OPV doses; 12 (32%) had 
received 1–3 OPV doses, and 17 (44%) had received 
≥4 OPV doses. WPV cases were found in 16 (5%) of 
325 districts in Afghanistan during 2009 and 2008, 
of which 12 and 13 were found in the South Region, 
respectively, including eight districts with confirmed 
WPV cases during both years. 
In Pakistan, 89 WPV cases (60 WPV1, 28 WPV3, 
and one WPV1/WPV3 mixed infection) were reported 
in 2009, compared with 118 cases (81 WPV1 and 37 
WPV3) during 2008 (Figure, Table 2). During 2009, 
a total of 81 (91%) WPV cases were among children 
aged <36 months; 32 (36%) had received no OPV 
doses; 18 (20%) had received 1–3 OPV doses, and 39 
(44%) had received ≥4 OPV doses. Of the 32 zero-
dose cases, 22 (69%) came from only two repeatedly 
inaccessible areas, Swat Valley District and Bajour 
Agency. WPV cases were found in 34 (25%) of 135 
districts in Pakistan during 2009, compared with 49 
(36%) districts in 2008. 
WPV genomic sequencing data from 2009 indi-
cated continued endemic WPV circulation in two 
main transmission zones of both countries. In the 
northern transmission zone, which includes most of 
NWFP and FATA in Pakistan and bordering areas 
in eastern Afghanistan (Figure), 52 WPV cases (35 
WPV1 and 17 WPV3) were reported during 2009. 
In the southern transmission zone, which extends 
from the West and South regions of Afghanistan into 
Pakistan through Balochistan and southern Punjab 
TABLE 2. Acute flaccid paralysis (AFP) surveillance indicators and number of reported wild poliovirus (WPV) cases — Afghanistan and Pakistan, 
2009*
Country/Area










WPV by quarter Total cases by type
1st 2nd 3rd 4th WPV1 WPV3
Afghanistan 1,470 8.5 93 6 7 11 14 15 23 38
Badakhshan 55 11.3 87 — — — — — — —
Northeast 233 12 95 — — — — — — —
North 228 9.7 94 — — — — — — —
Central 273 8.6 97 — 1 — — 1 — 1
West 190 6.9 97 — — 1 — 1 — 1
East 130 8.6 96 1 — — 1 1 1 2
Southeast 127 7.4 94 — — — — — — —
South 234 6.7 81 5 6 10 13 12 22 34
Pakistan 5,096 6.1 90 9 13 44 23 61 28 89
AJK, FANA, and ICT¶ 88 2.9 96 — — — — — — —
NWFP** 1042 9.2 87 2 2 18 7 24 5 29
FATA†† 164 7.6 86 2 2 13 3 9 11 20
Punjab 2,229 5.0 93 2 5 3 7 16 1 17
Balochistan 242 6.0 83 — 1 5 5 5 6 11
Sindh 1,331 7.0 90 3 3 5 1 7 5 12
 * Data as of February 2, 2010. All cases had onset of paralysis in 2009.
 † Per 100,000 children aged <15 years.
 § Two stool specimens collected at an interval of at least 24 hours within 14 days of paralysis onset and properly shipped to the laboratory.
 ¶ Azad Jammu and Kashmir (AJK), Federally Administered Northern Areas (FANA), and Islamabad Capital Territory (ICT).
 ** Northwest Frontier Province (NWFP).
 †† Federally Administered Tribal Areas (FATA).
 §§ Persistently affected districts in the Quetta area include Kila 
Abdullah, Pishin, and Quetta.
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into Sindh, including persistently affected districts in 
the Quetta area§§ and several towns in Karachi, 58 
cases (25 WPV1 and 33 WPV3) were reported dur-
ing 2009. In addition, 17 WPV1 cases were reported 
throughout Punjab Province during 2009, most of 
which represented continuation of a 2008 outbreak 
in northern Punjab (4). In addition to determining 
the origin and transmission zones of circulating WPV, 
genomic sequencing of polioviruses obtained from 
AFP cases and sewage samples also found polioviruses 
not closely related to other viruses. Because genetic 
sequences of polioviruses generally are highly related 
in sensitive surveillance systems, the detection of these 
distantly related viruses indicates missed detection of 
WPV cases and suggests that performance indicators 
are not revealing surveillance weaknesses in some 
subnational areas.
Reported by
World Health Organization (WHO) Eastern Mediterranean 
Regional Office, Cairo, Egypt; WHO Afghanistan, Kabul; 
WHO Pakistan, Islamabad; Polio Eradication Dept, WHO, 
Geneva, Switzerland. Global Immunization Div, Div of Viral 
Diseases, National Center for Immunization and Respiratory 
Diseases, CDC. 
Editorial Note
During 2009, the total number of WPV cases 
reported in Afghanistan and Pakistan did not substan-
tially change compared with 2008, and both WPV1 
and WPV3 serotypes continued to circulate in the 
FIGURE. Wild poliovirus (WPV) cases, by type and province or region* — Afghanistan and Pakistan, 2009†
* NWFP: Northwest Frontier Province (includes Federally Administered Tribal Areas); AJK: Azad, Jammu, and Kashmir; FANA: Federally 
Administered Northern Areas. 
† Data as of February 2, 2010. All cases had onset of paralysis in 2009.
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same two shared transmission zones of both countries 
as in 2008. However, WPV transmission remained 
largely limited to previously affected districts of both 
countries. Additionally, some improvement was made 
toward the end of 2009 in decreasing the proportion 
of children in inaccessible districts of both countries, 
primarily in Afghanistan. 
In Afghanistan, WPV transmission during the past 
5 years has remained largely restricted to 12 insecure 
districts in the South Region. Since 2008, multiple 
strategies have been implemented to immunize these 
children. As a result, the proportion of children in the 
South Region who are not vaccinated in a given SIA 
was reduced to 5% of the overall target population 
toward the end of 2009. Meanwhile, Afghanistan 
has been able to keep most of the country free of 
endemic WPV transmission despite extensive popu-
lation movements due to economic, social/cultural, 
and security reasons. 
In Pakistan, circulation of both WPV serotypes 
persists in both transmission zones, with WPV repeat-
edly occurring, primarily in nine districts during the 
past 5 years. In the northern zone, WPV transmission 
continues because of limited access to children during 
SIAs in insecure areas of NWFP and FATA. Large-
scale population movements from NWFP and FATA 
have caused renewed WPV transmission in polio-free 
areas. Access to districts in NWFP improved dur-
ing the last quarter of 2009, but access into FATA 
deteriorated. In the southern zone, WPV circulation 
continued mainly due to weak routine vaccination 
programs and managerial and operational gaps during 
SIAs, compounded by large-scale population move-
ments from insecure areas in southern Afghanistan. 
Substantial improvements in subnational account-
ability and oversight are needed to improve the quality 
of immunization activities in Pakistan. 
During 2010, planning, resources, and immuni-
zation activities need to focus on the small number 
of persistently affected districts in Afghanistan and 
Pakistan. In insecure areas, negotiations with com-
munity leaders need to be enhanced, and efforts are 
needed to achieve agreement of all parties to conflict 
regarding Days of Tranquility during SIAs to ensure 
access to the target population of children aged <5 
years and the safety of vaccination teams. Negotiations 
with conflict parties have been and will be supported 
by the International Federation of Red Cross and Red 
Crescent Societies. Coordination of both SIAs and 
AFP surveillance between both countries also needs 
to be strengthened further to interrupt transmission 
from cross-border movements. In addition, specific 
mechanisms need to be established to hold provincial, 
district, and local administrative leaders accountable 
for program performance. 
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What is already known on this topic?
Afghanistan and Pakistan are two of the four remain-
ing countries where indigenous wild poliovirus (WPV) 
transmission has never been interrupted.
What is added by this report?
Similar numbers of WPV cases were reported in 
Afghanistan and Pakistan in 2009 as in 2008, and both 
WPV1 and WPV3 serotypes continued to circulate in 
both countries; WPV transmission remained lim-
ited largely to previously affected districts of both 
countries.
What are the implications for public health practice?
Continued efforts to enhance safe access of vaccina-
tion teams in insecure areas are needed for interrup-
tion of WPV transmission in Afghanistan and Pakistan; 
also, substantial improvements in subnational 
accountability and oversight are needed to improve 
the quality of immunization activities in Pakistan.
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On February 19, 2010, the Food and Drug 
Administration (FDA) licensed a quadrivalent 
meningococcal conjugate vaccine, MenACWY-
CRM (Menveo, Novartis Vaccines and Diagnostics). 
MenACWY-CRM is licensed as a single dose for 
use among persons aged 11–55 years. The Advisory 
Committee on Immunization Practices (ACIP) 
reviewed data from prelicensure clinical trials on the 
safety and immunogenicity of MenACWY-CRM. 
This report summarizes the approved indications 
for MenACWY-CRM and provides guidance from 
ACIP for its use. The following guidance for use of 
MenACWY-CRM is consistent with licensed indica-
tions and ACIP recommendations for meningococcal 
conjugate vaccines. 
MenACWY-CRM consists of two components: 
1) 10 μg of lyophilized meningococcal serogroup 
A capsular polysaccharide conjugated to CRM197 
(MenA) and 2) 5 μg each of capsular polysaccharide 
of serogroup C, Y, and W135 conjugated to CRM197 
in 0.5 mL of phosphate buffered saline, which is used 
to reconstitute the lyophilized MenA component 
before injection (1). The reconstituted vaccine should 
be used immediately, but may be held at or below 
77°F (25°C) for up to 8 hours. MenACWY-CRM is 
administered as an intramuscular injection, preferably 
into the deltoid region (1). 
The capsular polysaccharide serogroups included 
in MenACWY-CRM are the same as those contained 
in Sanofi Pasteur’s MCV4 (Menactra). In study 
participants aged 11–18 years, noninferiority of 
MenACWY-CRM to MCV4 was demonstrated for 
all four serogroups using the primary endpoint, hSBA 
seroresponse (serum bactericidal assay using human 
complement). The proportions of subjects with hSBA 
seroresponse were statistically higher for serogroups 
A, W, and Y in the MenACWY-CRM group, com-
pared with the MCV4 group. The clinical relevance 
of higher postvaccination immune responses is not 
known (1). Safety and reactogenicity profiles were 
comparable to those observed with MCV4 (1). 
 Guidance for Use of MenACWY-CRM
MenACWY-CRM is licensed by the FDA as a 
single dose in persons aged 11–55 years (1). ACIP 
recommends quadrivalent meningococcal conjugate 
vaccine for all persons aged 11–18 years and for 
persons aged 2–55 years who are at increased risk 
for meningococcal disease. Persons at increased risk 
for meningococcal disease include 1) college fresh-
men living in dormitories, 2) microbiologists who 
are exposed routinely to isolates of Neisseria menin-
gitidis, 3) military recruits, 4) persons who travel to 
or reside in countries where meningococcal disease 
is hyperendemic or epidemic, 5) persons who have 
persistent complement component deficiencies, and 
6) persons with anatomic or functional asplenia (2). 
MenACWY-CRM or MCV4 may be used in persons 
aged 11–55 years, and are preferred to quadrivalent 
meningococcal polysaccharide vaccine (MPSV4) 
(2). Persons aged 2–10 years who are recommended 
to receive a meningococcal vaccine should receive 
MCV4, and persons aged >55 years should receive 
MPSV4 (3). 
Severe allergic reaction (e.g., anaphylaxis) after 
a previous dose of Menveo, any component of this 
vaccine, or any other CRM197, diphtheria toxoid, or 
meningococcal-containing vaccine is a contraindica-
tion to administration of Menveo. Details regard-
ing the recommended meningococcal vaccination 
schedule are available at http://www.cdc.gov/vaccines/
recs/schedules/default.htm#child. Adverse events 
after receipt of any vaccine should be reported to the 
Vaccine Adverse Event Reporting System at http://
vaers.hhs.gov.
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TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 









Total cases reported 
for previous years States reporting cases 
during current week (No.)2009 2008 2007 2006 2005
Anthrax — — 0 1 — 1 1 —
Botulism, total — 7 2 99 145 144 165 135
 foodborne — — 0 11 17 32 20 19
 infant — 6 2 64 109 85 97 85
 other (wound and unspecified) — 1 0 24 19 27 48 31
Brucellosis 1 8 2 110 80 131 121 120 CA (1)
Chancroid 1 15 1 46 25 23 33 17 VA (1)
Cholera — — — 8 5 7 9 8
Cyclosporiasis§ 1 9 1 128 139 93 137 543 FL (1)
Diphtheria — — — — — — — —
Domestic arboviral diseases § ,¶:
 California serogroup virus disease — — 0 54 62 55 67 80
 Eastern equine encephalitis virus disease — — — 4 4 4 8 21
 Powassan virus disease — — — 6 2 7 1 1
 St. Louis encephalitis virus disease — — 0 12 13 9 10 13
 Western equine encephalitis virus disease — — — — — — — —
Haemophilus influenzae,** invasive disease (age <5 yrs):
 serotype b — 2 1 27 30 22 29 9
 nonserotype b — 23 5 215 244 199 175 135
 unknown serotype 3 48 4 231 163 180 179 217 FL (3)
Hansen disease§ — 6 1 73 80 101 66 87
Hantavirus pulmonary syndrome§ — 1 0 13 18 32 40 26
Hemolytic uremic syndrome, postdiarrheal§ 4 19 2 231 330 292 288 221 GA (1), FL (2), CA (1)
HIV infection, pediatric (age <13 yrs)†† — — 3 — — — — 380
Influenza-associated pediatric mortality§,§§ — 39 4 360 90 77 43 45
Listeriosis 6 69 9 794 759 808 884 896 NY (1), MN (1), NC (1), FL (1), TN (1), WA (1)
Measles¶¶ — 2 1 65 140 43 55 66
Meningococcal disease, invasive***:
 A, C, Y, and W-135 4 34 11 286 330 325 318 297 MN (1), OK (1), WA (2)
 serogroup B — 19 5 148 188 167 193 156
 other serogroup — 1 1 24 38 35 32 27
 unknown serogroup 6 65 17 477 616 550 651 765 OH (2), FL (1), ID (1), CA (2)
Mumps 81 484 20 1,443 454 800 6,584 314 NY (78), OH (1), TN (1), TX (1)
Novel influenza A virus infections††† — — 0 43,771 2 4 NN NN
Plague — — 0 8 3 7 17 8
Poliomyelitis, paralytic — — — — — — — 1
Polio virus Infection, nonparalytic§ — — — — — — NN NN
Psittacosis§ — 1 0 9 8 12 21 16
Q fever, total§,§§§ 2 8 2 100 120 171 169 136
 acute 1 5 1 83 106 — — — CA (1)
 chronic 1 3 0 17 14 — — — FL (1)
Rabies, human — — — 4 2 1 3 2
Rubella¶¶¶ — 1 0 3 16 12 11 11
Rubella, congenital syndrome — — 0 1 — — 1 1
SARS-CoV§,**** — — — — — — — —
Smallpox§ — — — — — — — —
Streptococcal toxic-shock syndrome§ 1 15 4 139 157 132 125 129 WV (1)
Syphilis, congenital (age <1 yr) — 11 7 318 431 430 349 329
Tetanus — — 0 16 19 28 41 27
Toxic-shock syndrome (staphylococcal)§ — 13 2 74 71 92 101 90
Trichinellosis — — 0 11 39 5 15 16
Tularemia — 1 0 88 123 137 95 154
Typhoid fever 4 51 6 345 449 434 353 324 FL (1), AZ (1), CA (2)
Vancomycin-intermediate Staphylococcus aureus§ 2 7 1 72 63 37 6 2 NY (2)
Vancomycin-resistant Staphylococcus aureus§ — — — — — 2 1 3
Vibriosis (noncholera Vibrio species infections)§ 1 19 2 706 588 549 NN NN CA (1)
Viral Hemorrhagic Fever†††† — — — NN NN NN NN NN
Yellow fever — — — — — — — —
See Table I footnotes on next page.
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* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the 
past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week 
totals.
FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week 
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TABLE I. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending 
March 6, 2010 (9th week)*
—: No reported cases. N: Not reportable. NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts.
 * Incidence data for reporting years 2009 and 2010 are provisional, whereas data for 2005 through 2008 are finalized.
 † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. 
Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and 
Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
 ** Data for H. influenzae (all ages, all serotypes) are available in Table II.
 †† Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences 
the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is 
completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
 §§ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Since April 26, 2009, a total of 278 influenza-associated pediatric 
deaths associated with 2009 influenza A (H1N1) virus infection have been reported. Since August 30, 2009, a total of 265 influenza-associated pediatric deaths occurring during the 
2009–10 influenza season have been reported. A total of 133 influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
 ¶¶ No measles cases were reported for the current week.
 *** Data for meningococcal disease (all serogroups) are available in Table II.
 ††† CDC discontinued reporting of individual confirmed and probable cases of 2009 pandemic influenza A (H1N1) virus infections on July 24, 2009. CDC will report the total number of 2009 
pandemic influenza A (H1N1) hospitalizations and deaths weekly on the CDC H1N1 influenza website (http://www.cdc.gov/h1n1flu). In addition, three cases of novel influenza A virus 
infections, unrelated to the 2009 pandemic influenza A (H1N1) virus, were reported to CDC during 2009.
 §§§ In 2009, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with 
respect to acute and chronic Q fever cases.
 ¶¶¶ No rubella cases were reported for the current week.
 **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.
 †††† There were no cases of Viral Hemorrhagic Fever during week one. See Table II for Dengue Hemorrhagic Fever.
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TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Reporting area
Chlamydia trachomatis infection Cryptosporidiosis
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 9,521 23,111 27,367 150,222 218,039 52 116 261 683 724
New England 624 759 1,194 5,618 6,945 — 6 24 36 81
Connecticut — 220 531 859 1,905 — 0 12 12 40
Maine† — 47 75 381 475 — 1 4 10 3
Massachusetts 537 374 767 3,455 3,480 — 2 15 — 24
New Hampshire 1 39 60 143 385 — 1 5 4 8
Rhode Island† 53 67 244 578 508 — 0 8 1 1
Vermont† 33 23 63 202 192 — 1 9 9 5
Mid. Atlantic 1,473 3,002 4,296 24,969 26,697 2 14 37 63 79
New Jersey 316 398 630 2,739 4,427 — 0 5 — 5
New York (Upstate) 639 607 2,155 4,764 4,490 1 3 16 12 23
New York City — 1,184 2,289 10,245 10,283 — 1 5 4 15
Pennsylvania 518 816 1,010 7,221 7,497 1 9 19 47 36
E.N. Central 795 3,454 4,167 16,119 36,001 10 27 55 148 180
Illinois — 1,015 1,219 137 11,017 — 3 8 12 21
Indiana — 391 694 685 3,940 — 4 9 5 35
Michigan 682 881 1,330 8,771 8,520 2 6 11 46 36
Ohio 113 671 986 3,732 8,840 8 7 16 43 47
Wisconsin — 386 480 2,794 3,684 — 9 24 42 41
W.N. Central 455 1,310 1,703 8,183 12,473 14 19 61 95 71
Iowa 8 169 252 659 1,770 1 4 13 21 16
Kansas — 182 561 1,234 1,785 — 2 6 10 7
Minnesota — 269 338 789 2,642 11 5 34 34 12
Missouri 387 507 638 4,440 4,510 — 3 12 11 17
Nebraska† 60 106 236 851 936 2 2 9 13 11
North Dakota — 31 92 210 298 — 0 5 — —
South Dakota — 44 80 — 532 — 1 10 6 8
S. Atlantic 1,784 4,610 6,207 25,440 41,847 10 17 49 152 153
Delaware 97 86 180 722 833 — 0 2 1 —
District of Columbia — 120 178 627 1,332 — 0 1 — 1
Florida 598 1,414 1,671 11,205 13,097 4 7 24 57 50
Georgia 2 672 1,134 52 6,863 2 5 31 74 66
Maryland† 501 447 1,031 2,895 3,448 2 1 5 5 5
North Carolina — 650 1,265 — 7,333 — 0 8 — 20
South Carolina† — 523 1,421 4,214 3,913 — 1 7 5 4
Virginia† 519 620 926 5,134 4,302 1 1 7 7 6
West Virginia 67 67 136 591 726 1 0 2 3 1
E.S. Central 1,482 1,697 2,231 12,190 15,925 4 4 10 30 21
Alabama† — 453 629 2,266 4,332 — 1 5 4 6
Kentucky 325 223 642 2,007 2,203 2 1 4 11 3
Mississippi 618 430 840 3,019 4,025 — 0 3 4 4
Tennessee† 539 579 734 4,898 5,365 2 1 5 11 8
W.S. Central 520 3,050 5,787 23,865 28,555 3 8 37 32 33
Arkansas† 314 269 416 2,389 2,739 — 1 5 8 3
Louisiana — 520 1,055 2,922 5,493 — 0 6 — 4
Oklahoma 206 202 2,714 3,077 1,277 1 2 9 5 5
Texas† — 2,040 3,079 15,477 19,046 2 5 22 19 21
Mountain 552 1,371 2,096 9,693 12,871 4 10 26 63 46
Arizona 137 487 755 2,612 3,989 — 0 3 2 5
Colorado 255 353 689 3,294 2,786 1 2 10 17 8
Idaho† — 61 184 318 664 3 2 7 17 5
Montana† — 54 86 378 602 — 1 4 8 2
Nevada† 151 171 478 1,442 2,144 — 0 2 1 —
New Mexico† — 172 257 664 1,157 — 2 8 9 19
Utah 9 112 142 715 1,170 — 0 4 6 2
Wyoming† — 36 69 270 359 — 0 2 3 5
Pacific 1,836 3,463 4,815 24,145 36,725 5 13 26 64 60
Alaska — 98 128 723 987 — 0 1 1 1
California 1,556 2,638 3,907 18,745 28,772 5 6 17 37 34
Hawaii — 120 147 767 1,045 — 0 1 — —
Oregon — 217 468 1,367 1,790 — 3 10 17 22
Washington 280 392 525 2,543 4,131 — 1 13 9 3
American Samoa — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico 120 130 331 1,030 1,289 N 0 0 N N
U.S. Virgin Islands — 9 17 19 38 — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Dengue Virus Infection
Reporting area
Dengue Fever Dengue Hemorrhagic Fever†
Current  
week






Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States — 0 3 7 NN — 0 0 — NN
New England — 0 1 1 NN — 0 0 — NN
Connecticut — 0 0 — NN — 0 0 — NN
Maine§ — 0 1 1 NN — 0 0 — NN
Massachusetts — 0 0 — NN — 0 0 — NN
New Hampshire — 0 0 — NN — 0 0 — NN
Rhode Island§ — 0 0 — NN — 0 0 — NN
Vermont§ — 0 0 — NN — 0 0 — NN
Mid. Atlantic — 0 1 2 NN — 0 0 — NN
New Jersey — 0 0 — NN — 0 0 — NN
New York (Upstate) — 0 0 — NN — 0 0 — NN
New York City — 0 0 — NN — 0 0 — NN
Pennsylvania — 0 1 2 NN — 0 0 — NN
E.N. Central — 0 1 1 NN — 0 0 — NN
Illinois — 0 0 — NN — 0 0 — NN
Indiana — 0 0 — NN — 0 0 — NN
Michigan — 0 0 — NN — 0 0 — NN
Ohio — 0 1 1 NN — 0 0 — NN
Wisconsin — 0 0 — NN — 0 0 — NN
W.N. Central — 0 0 — NN — 0 0 — NN
Iowa — 0 0 — NN — 0 0 — NN
Kansas — 0 0 — NN — 0 0 — NN
Minnesota — 0 0 — NN — 0 0 — NN
Missouri — 0 0 — NN — 0 0 — NN
Nebraska§ — 0 0 — NN — 0 0 — NN
North Dakota — 0 0 — NN — 0 0 — NN
South Dakota — 0 0 — NN — 0 0 — NN
S. Atlantic — 0 1 1 NN — 0 0 — NN
Delaware — 0 0 — NN — 0 0 — NN
District of Columbia — 0 0 — NN — 0 0 — NN
Florida — 0 0 — NN — 0 0 — NN
Georgia — 0 1 1 NN — 0 0 — NN
Maryland§ — 0 0 — NN — 0 0 — NN
North Carolina — 0 0 — NN — 0 0 — NN
South Carolina§ — 0 0 — NN — 0 0 — NN
Virginia§ — 0 0 — NN — 0 0 — NN
West Virginia — 0 0 — NN — 0 0 — NN
E.S. Central — 0 0 — NN — 0 0 — NN
Alabama§ — 0 0 — NN — 0 0 — NN
Kentucky — 0 0 — NN — 0 0 — NN
Mississippi — 0 0 — NN — 0 0 — NN
Tennessee§ — 0 0 — NN — 0 0 — NN
W.S. Central — 0 0 — NN — 0 0 — NN
Arkansas§ — 0 0 — NN — 0 0 — NN
Louisiana — 0 0 — NN — 0 0 — NN
Oklahoma — 0 0 — NN — 0 0 — NN
Texas§ — 0 0 — NN — 0 0 — NN
Mountain — 0 0 — NN — 0 0 — NN
Arizona — 0 0 — NN — 0 0 — NN
Colorado — 0 0 — NN — 0 0 — NN
Idaho§ — 0 0 — NN — 0 0 — NN
Montana§ — 0 0 — NN — 0 0 — NN
Nevada§ — 0 0 — NN — 0 0 — NN
New Mexico§ — 0 0 — NN — 0 0 — NN
Utah — 0 0 — NN — 0 0 — NN
Wyoming§ — 0 0 — NN — 0 0 — NN
Pacific — 0 2 2 NN — 0 0 — NN
Alaska — 0 0 — NN — 0 0 — NN
California — 0 0 — NN — 0 0 — NN
Hawaii — 0 0 — NN — 0 0 — NN
Oregon — 0 0 — NN — 0 0 — NN
Washington — 0 2 2 NN — 0 0 — NN
American Samoa — 0 0 — NN — 0 0 — NN
C.N.M.I. — — — — NN — — — — NN
Guam — 0 0 — NN — 0 0 — NN
Puerto Rico — 0 0 — NN — 0 0 — NN
U.S. Virgin Islands — 0 0 — NN — 0 0 — NN
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† DHF includes cases that meet criteria for dengue shock syndrome (DSS), a more severe form of DHF.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Ehrlichiosis/Anaplasmosis†
Reporting area
Ehrlichia chaffeensis Anaplasma phagocytophilum Undetermined
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 4 11 58 17 20 — 13 64 8 9 — 2 13 1 1
New England — 0 4 1 1 — 2 21 4 3 — 0 2 — —
Connecticut — 0 0 — — — 0 11 — — — 0 1 — —
Maine§ — 0 1 1 — — 0 3 2 — — 0 0 — —
Massachusetts — 0 0 — — — 0 0 — — — 0 0 — —
New Hampshire — 0 1 — — — 0 3 — 1 — 0 1 — —
Rhode Island§ — 0 4 — 1 — 0 20 2 2 — 0 1 — —
Vermont§ — 0 1 — — — 0 0 — — — 0 0 — —
Mid. Atlantic 1 2 17 2 1 — 3 22 1 — — 0 2 — —
New Jersey — 0 1 — — — 0 0 — — — 0 0 — —
New York (Upstate) 1 1 17 1 — — 3 21 1 — — 0 1 — —
New York City — 0 3 — 1 — 0 1 — — — 0 2 — —
Pennsylvania — 0 1 1 — — 0 0 — — — 0 0 — —
E.N. Central — 1 8 — — — 3 22 1 2 — 1 9 — —
Illinois — 0 4 — — — 0 1 — — — 0 1 — —
Indiana — 0 0 — — — 0 0 — — — 0 8 — —
Michigan — 0 0 — — — 0 0 — — — 0 0 — —
Ohio — 0 2 — — — 0 1 — — — 0 1 — —
Wisconsin — 0 5 — — — 3 22 1 2 — 0 3 — —
W.N. Central — 2 23 1 1 — 0 41 — — — 0 5 1 —
Iowa — 0 0 — — — 0 0 — — — 0 0 — —
Kansas — 0 2 — — — 0 0 — — — 0 0 — —
Minnesota — 0 3 — 1 — 0 41 — — — 0 5 — —
Missouri — 1 22 1 — — 0 1 — — — 0 3 1 —
Nebraska§ — 0 1 — — — 0 1 — — — 0 0 — —
North Dakota — 0 0 — — — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — — — 0 0 — —
S. Atlantic 3 3 19 12 15 — 0 2 2 3 — 0 2 — —
Delaware — 0 2 1 1 — 0 1 — — — 0 0 — —
District of Columbia — 0 0 — — — 0 0 — — — 0 0 — —
Florida — 0 1 1 2 — 0 1 — — — 0 0 — —
Georgia — 0 2 3 3 — 0 1 1 1 — 0 0 — —
Maryland§ — 1 4 4 4 — 0 1 — 1 — 0 1 — —
North Carolina 3 0 4 3 5 — 0 1 1 1 — 0 0 — —
South Carolina§ — 0 1 — — — 0 0 — — — 0 0 — —
Virginia§ — 1 13 — — — 0 1 — — — 0 2 — —
West Virginia — 0 1 — — — 0 0 — — — 0 0 — —
E.S. Central — 1 11 — 2 — 0 1 — 1 — 0 5 — 1
Alabama§ — 0 3 — — — 0 1 — — — 0 0 — —
Kentucky — 0 2 — — — 0 0 — — — 0 1 — —
Mississippi — 0 0 — — — 0 0 — — — 0 0 — —
Tennessee§ — 1 10 — 2 — 0 1 — 1 — 0 5 — 1
W.S. Central — 0 9 1 — — 0 1 — — — 0 0 — —
Arkansas§ — 0 5 — — — 0 0 — — — 0 0 — —
Louisiana — 0 0 — — — 0 0 — — — 0 0 — —
Oklahoma — 0 8 — — — 0 1 — — — 0 0 — —
Texas§ — 0 1 1 — — 0 1 — — — 0 0 — —
Mountain — 0 0 — — — 0 0 — — — 0 1 — —
Arizona — 0 0 — — — 0 0 — — — 0 1 — —
Colorado — 0 0 — — — 0 0 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 0 — — — 0 0 — —
Montana§ — 0 0 — — — 0 0 — — — 0 0 — —
Nevada§ — 0 0 — — — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — — — 0 0 — —
Utah — 0 0 — — — 0 0 — — — 0 0 — —
Wyoming§ — 0 0 — — — 0 0 — — — 0 0 — —
Pacific — 0 1 — — — 0 0 — — — 0 0 — —
Alaska — 0 0 — — — 0 0 — — — 0 0 — —
California — 0 1 — — — 0 0 — — — 0 0 — —
Hawaii — 0 0 — — — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Cumulative total E. ewingii cases reported as of this week = 0.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Reporting area
Giardiasis Gonorrhea
Haemophilus influenzae, invasive†  
All ages, all serotypes
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 154 327 575 2,146 2,622 2,031 5,451 6,889 34,454 53,634 25 54 140 420 601
New England 4 29 64 121 217 53 94 174 714 881 — 3 19 7 30
Connecticut 1 6 15 51 44 — 46 106 245 394 — 0 13 — 5
Maine§ 1 4 13 26 32 — 3 11 42 17 — 0 2 1 3
Massachusetts — 13 36 — 89 43 38 81 348 397 — 2 8 — 18
New Hampshire — 3 12 17 18 5 2 6 26 18 — 0 2 4 3
Rhode Island§ — 1 6 2 11 4 6 19 46 49 — 0 2 2 —
Vermont§ 2 4 14 25 23 1 1 5 7 6 — 0 1 — 1
Mid. Atlantic 18 61 100 358 488 281 599 840 5,167 5,468 7 12 26 112 100
New Jersey — 0 12 — 82 55 87 128 707 827 — 1 7 6 15
New York (Upstate) 13 25 80 166 162 74 101 353 729 922 4 3 18 35 25
New York City — 15 26 89 143 — 215 417 1,984 1,968 — 2 11 16 15
Pennsylvania 5 16 35 103 101 152 195 275 1,747 1,751 3 4 10 55 45
E.N. Central 16 45 74 319 396 194 1,046 1,346 4,427 11,414 — 10 29 58 144
Illinois — 11 21 44 87 — 325 382 47 3,436 — 3 10 10 29
Indiana N 0 0 N N — 121 209 227 1,370 — 1 5 11 16
Michigan 1 13 25 84 105 175 256 503 2,543 2,929 — 0 4 1 4
Ohio 15 16 28 142 127 19 227 357 1,037 2,694 — 2 6 23 21
Wisconsin — 9 19 49 77 — 92 146 573 985 — 3 21 13 74
W.N. Central 7 25 155 161 202 95 271 361 1,667 2,739 2 2 21 19 31
Iowa 1 5 15 41 47 — 31 46 86 286 — 0 0 — —
Kansas — 3 14 31 20 — 41 85 217 460 — 0 2 3 5
Minnesota — 0 135 — 1 — 41 64 115 421 1 0 17 2 7
Missouri — 9 27 47 87 81 122 172 1,065 1,229 — 1 6 10 12
Nebraska§ 6 3 9 36 28 14 23 54 170 259 1 0 3 2 6
North Dakota — 0 8 — 2 — 2 14 14 14 — 0 2 2 1
South Dakota — 0 5 6 17 — 3 14 — 70 — 0 0 — —
S. Atlantic 46 72 107 532 644 479 1,342 1,790 7,134 12,570 6 12 31 96 149
Delaware 1 0 3 8 4 17 18 37 164 178 — 0 1 1 1
District of Columbia — 0 2 — 12 — 47 88 251 543 — 0 1 — —
Florida 33 37 59 285 325 177 408 476 3,126 3,735 5 4 10 31 51
Georgia — 10 67 101 172 — 215 415 23 2,401 1 3 9 39 28
Maryland§ 6 5 12 42 48 118 123 242 805 962 — 1 6 7 17
North Carolina N 0 0 N N — 219 377 — 2,487 — 0 17 — 16
South Carolina§ — 2 8 15 14 — 160 412 1,247 1,181 — 1 7 17 8
Virginia§ 6 8 33 76 62 150 159 272 1,444 972 — 0 3 — 18
West Virginia — 1 5 5 7 17 8 18 74 111 — 0 4 1 10
E.S. Central — 7 22 35 69 420 471 649 3,429 4,774 1 3 12 26 38
Alabama§ — 4 13 15 37 — 133 187 692 1,324 — 0 4 2 8
Kentucky N 0 0 N N 89 63 156 602 634 — 0 5 2 4
Mississippi N 0 0 N N 184 134 249 872 1,292 — 0 2 3 3
Tennessee§ — 4 18 20 32 147 153 206 1,263 1,524 1 2 10 19 23
W.S. Central 2 7 19 35 49 134 898 1,553 6,368 8,323 3 2 9 19 24
Arkansas§ — 3 9 17 10 76 86 139 686 792 — 0 3 2 5
Louisiana — 0 7 — 31 — 165 343 910 1,846 — 0 1 — 5
Oklahoma 2 3 10 18 8 58 63 613 816 462 3 1 7 16 13
Texas§ N 0 0 N N — 560 917 3,956 5,223 — 0 2 1 1
Mountain 21 26 61 230 209 64 164 239 1,114 1,644 6 5 13 68 59
Arizona 4 3 11 25 23 11 57 93 327 476 1 1 9 24 27
Colorado 14 9 26 114 65 22 40 99 359 511 4 1 6 20 14
Idaho§ 3 3 10 35 21 — 1 8 6 20 — 0 1 2 1
Montana§ — 2 11 12 17 — 1 5 17 12 — 0 1 — 1
Nevada§ — 1 10 5 5 31 26 94 275 392 — 0 2 4 4
New Mexico§ — 1 8 6 19 — 21 36 100 161 1 1 5 11 5
Utah — 5 13 23 47 — 5 13 28 63 — 1 2 2 7
Wyoming§ — 1 5 10 12 — 1 7 2 9 — 0 2 5 —
Pacific 40 51 148 355 348 311 533 638 4,434 5,821 — 3 9 15 26
Alaska — 2 7 9 10 — 19 32 176 154 — 0 3 5 3
California 32 33 60 245 258 283 438 531 3,736 4,858 — 0 4 — 8
Hawaii — 0 2 — 3 — 12 24 104 104 — 0 5 — 6
Oregon — 8 18 60 50 — 19 44 106 219 — 1 4 8 8
Washington 8 7 95 41 27 28 40 64 312 486 — 0 4 2 1
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 1 10 1 24 5 4 24 42 30 — 0 1 1 —
U.S. Virgin Islands — 0 0 — — — 2 7 5 16 N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for H. influenzae (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*

















Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 21 35 57 201 336 25 57 96 338 654 9 17 39 94 136
New England — 2 5 8 18 — 1 3 4 8 — 1 5 2 9
Connecticut — 0 2 7 5 — 0 3 3 3 — 1 4 2 6
Maine† — 0 1 1 1 — 0 2 1 1 — 0 2 — —
Massachusetts — 1 4 — 10 — 0 2 — 3 — 0 1 — 2
New Hampshire — 0 1 — 1 — 0 1 — 1 — 0 0 — —
Rhode Island† — 0 1 — 1 — 0 0 — — — 0 0 — —
Vermont† — 0 1 — — — 0 0 — — — 0 0 — 1
Mid. Atlantic 3 4 10 27 49 1 5 16 24 69 2 2 7 11 15
New Jersey — 0 5 2 15 — 1 6 — 15 — 0 1 — 1
New York (Upstate) 2 1 3 7 7 — 1 6 6 14 1 1 4 8 5
New York City — 2 5 10 13 — 1 5 9 11 — 0 0 — —
Pennsylvania 1 1 6 8 14 1 1 6 9 29 1 0 4 3 9
E.N. Central — 5 19 20 58 2 6 14 41 107 1 4 12 18 32
Illinois — 2 13 1 21 — 1 6 — 20 — 0 1 — 3
Indiana — 0 4 — 4 — 1 5 7 16 — 0 4 — 2
Michigan — 1 4 6 14 — 2 6 17 27 1 3 10 17 16
Ohio — 0 4 8 13 2 1 4 17 34 — 0 4 1 10
Wisconsin — 0 2 5 6 — 0 4 — 10 — 0 2 — 1
W.N. Central — 2 7 7 15 1 3 10 24 34 — 1 7 5 3
Iowa — 0 3 3 — — 0 3 3 7 — 0 4 — 1
Kansas — 0 2 3 1 — 0 2 1 1 — 0 1 — —
Minnesota — 0 4 — 4 — 0 9 — 4 — 0 6 — —
Missouri — 0 3 1 6 — 2 5 14 16 — 0 2 3 1
Nebraska† — 0 3 — 4 1 0 2 6 5 — 0 1 1 1
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — — — 0 1 — 1 — 0 1 1 —
S. Atlantic 4 8 14 46 75 6 15 32 115 208 3 4 12 20 27
Delaware — 0 1 2 — U 0 0 U U U 0 0 U U
District of Columbia U 0 0 U U U 0 0 U U U 0 0 U U
Florida 4 3 9 25 41 4 5 13 53 56 2 1 4 10 2
Georgia — 1 3 6 11 — 3 7 28 35 — 0 3 1 6
Maryland† — 1 3 2 8 2 1 6 12 27 1 1 3 5 6
North Carolina — 0 7 — 6 — 0 19 2 74 — 0 10 — 4
South Carolina† — 1 4 7 5 — 1 4 6 1 — 0 1 — —
Virginia† — 1 3 4 4 — 1 12 8 12 — 0 2 3 4
West Virginia — 0 2 — — — 0 19 6 3 — 0 2 1 5
E.S. Central — 1 3 7 9 2 7 13 50 71 1 2 5 18 19
Alabama† — 0 2 2 1 — 1 5 12 22 — 0 2 1 1
Kentucky — 0 2 3 1 1 2 6 21 12 1 1 5 16 10
Mississippi — 0 1 — 4 — 0 2 — 4 — 0 0 — —
Tennessee† — 0 2 2 3 1 3 6 17 33 — 0 3 1 8
W.S. Central 4 3 15 19 30 4 9 19 24 77 2 1 6 6 8
Arkansas† — 0 2 — 3 — 1 4 — 7 — 0 1 — 1
Louisiana — 0 1 — 2 — 0 4 — 11 — 0 1 — 1
Oklahoma — 0 3 1 1 3 2 8 6 9 1 0 4 2 —
Texas† 4 3 15 18 24 1 6 15 18 50 1 0 4 4 6
Mountain 4 3 8 32 23 — 2 5 8 32 — 1 4 5 12
Arizona 4 1 5 23 11 — 0 3 2 13 — 0 0 — —
Colorado — 1 5 5 6 — 0 2 1 6 — 0 3 — 8
Idaho† — 0 1 2 — — 0 2 1 1 — 0 2 3 —
Montana† — 0 1 — 2 — 0 0 — — — 0 0 — —
Nevada† — 0 2 1 — — 0 3 4 5 — 0 1 — —
New Mexico† — 0 1 1 1 — 0 1 — 4 — 0 1 — 4
Utah — 0 2 — 3 — 0 1 — 3 — 0 2 2 —
Wyoming† — 0 1 — — — 0 2 — — — 0 0 — —
Pacific 6 5 16 35 59 9 6 25 48 48 — 1 6 9 11
Alaska — 0 1 — 1 — 0 1 1 — — 0 2 — —
California 6 4 15 31 50 9 4 17 39 40 — 1 4 4 7
Hawaii — 0 2 — 1 — 0 1 — 1 — 0 0 — —
Oregon — 0 2 2 4 — 1 4 5 5 — 0 3 4 2
Washington — 1 3 2 3 — 0 8 3 2 — 0 6 1 2
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 2 2 7 — 0 5 1 1 — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Reporting area
Legionellosis Lyme disease Malaria
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 19 56 163 269 303 54 369 2,013 902 1,358 6 22 54 172 165
New England — 2 18 6 11 4 72 493 34 235 — 1 4 — 9
Connecticut — 1 5 3 4 — 0 0 — — — 0 3 — —
Maine† — 0 3 — — 4 11 76 26 17 — 0 1 — —
Massachusetts — 1 9 — 6 — 29 328 — 129 — 0 3 — 8
New Hampshire — 0 2 1 — — 19 93 3 69 — 0 1 — —
Rhode Island† — 0 4 1 — — 1 28 — 1 — 0 1 — —
Vermont† — 0 1 1 1 — 5 42 5 19 — 0 1 — 1
Mid. Atlantic 3 16 69 52 78 24 190 1,111 494 620 1 6 13 40 29
New Jersey — 2 13 — 10 — 37 378 19 242 — 0 1 — —
New York (Upstate) 3 5 29 23 24 12 52 339 120 123 1 1 4 13 7
New York City — 3 20 8 6 — 2 25 — 13 — 4 11 21 17
Pennsylvania — 6 25 21 38 12 103 644 355 242 — 1 4 6 5
E.N. Central 3 10 38 47 67 — 23 223 50 74 1 3 11 15 24
Illinois — 1 10 1 7 — 1 11 — 1 — 1 5 5 10
Indiana — 1 4 2 9 — 1 7 4 3 — 0 4 1 5
Michigan — 2 13 8 11 — 1 9 2 1 — 0 3 3 2
Ohio 3 5 17 34 33 — 1 5 3 2 1 0 6 6 7
Wisconsin — 1 5 2 7 — 20 205 41 67 — 0 1 — —
W.N. Central 1 2 12 8 4 — 5 196 1 14 — 1 8 12 8
Iowa — 0 2 — 2 — 0 14 — 5 — 0 1 1 3
Kansas — 0 1 1 2 — 0 2 — 4 — 0 1 3 1
Minnesota 1 0 11 3 — — 0 196 — 4 — 0 8 3 1
Missouri — 1 5 2 — — 0 1 — — — 0 1 2 3
Nebraska† — 0 2 2 — — 0 3 1 — — 0 2 3 —
North Dakota — 0 1 — — — 0 0 — — — 0 1 — —
South Dakota — 0 1 — — — 0 0 — 1 — 0 1 — —
S. Atlantic 5 11 22 63 67 22 65 246 280 386 2 6 16 49 63
Delaware — 0 5 3 — 6 13 65 75 75 — 0 1 1 1
District of Columbia — 0 2 — 1 — 0 5 — 2 — 0 2 1 4
Florida 2 4 10 27 26 2 2 11 13 6 1 2 7 25 15
Georgia 2 1 4 8 14 — 1 5 1 12 — 1 5 2 10
Maryland† 1 3 12 13 10 7 27 131 131 235 1 1 13 10 20
North Carolina — 0 5 — 12 4 0 14 4 7 — 0 3 — 8
South Carolina† — 0 2 1 1 — 0 3 2 3 — 0 1 — 1
Virginia† — 1 6 10 3 3 11 65 46 37 — 1 5 10 4
West Virginia — 0 2 1 — — 0 33 8 9 — 0 2 — —
E.S. Central — 2 12 12 16 — 1 4 6 3 — 0 3 3 6
Alabama† — 0 2 1 2 — 0 1 — — — 0 3 1 1
Kentucky — 1 3 5 6 — 0 1 1 — — 0 3 2 —
Mississippi — 0 2 — — — 0 0 — — — 0 1 — —
Tennessee† — 1 9 6 8 — 1 4 5 3 — 0 2 — 5
W.S. Central — 2 7 9 8 — 4 24 1 3 — 1 19 30 5
Arkansas† — 0 1 — — — 0 0 — — — 0 1 1 —
Louisiana — 0 2 — 1 — 0 0 — — — 0 1 — 1
Oklahoma — 0 2 — — — 0 0 — — — 0 1 1 —
Texas† — 2 6 9 7 — 4 24 1 3 — 1 19 28 4
Mountain 1 2 8 17 20 — 1 4 3 2 — 0 6 5 3
Arizona 1 1 5 10 6 — 0 1 — — — 0 2 1 —
Colorado — 0 4 2 2 — 0 1 1 — — 0 3 — 1
Idaho† — 0 2 — 1 — 0 3 1 1 — 0 1 — —
Montana† — 0 1 1 3 — 0 1 — — — 0 3 — —
Nevada† — 0 1 2 3 — 0 1 — — — 0 1 1 —
New Mexico† — 0 2 1 — — 0 1 — — — 0 0 — —
Utah — 0 4 1 5 — 0 1 1 1 — 0 1 3 2
Wyoming† — 0 2 — — — 0 1 — — — 0 0 — —
Pacific 6 3 19 55 32 4 3 10 33 21 2 2 17 18 18
Alaska — 0 1 — 1 — 0 1 1 2 — 0 1 — —
California 5 3 19 54 25 4 2 9 24 16 1 2 12 14 13
Hawaii — 0 0 — 1 N 0 0 N N — 0 1 — —
Oregon — 0 2 — 3 — 1 4 8 3 — 0 2 — 2
Washington 1 0 4 1 2 — 0 3 — — 1 0 4 4 3
American Samoa N 0 0 N N N 0 0 N N — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 1 — — N 0 0 N N — 0 1 1 1
U.S. Virgin Islands — 0 0 — — N 0 0 N N — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Reporting area
Meningococcal disease, invasive† 
All groups Pertussis Rabies, animal
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 10 16 32 119 185 55 266 1,341 1,018 2,082 34 62 139 291 583
New England — 0 3 — 11 — 10 24 8 114 2 6 24 34 41
Connecticut — 0 2 — 1 — 1 4 — 5 1 2 22 15 16
Maine§ — 0 1 — 1 — 0 10 1 21 1 1 4 9 6
Massachusetts — 0 2 — 7 — 6 16 — 70 — 0 0 — —
New Hampshire — 0 1 — 1 — 1 7 2 10 — 0 3 2 4
Rhode Island§ — 0 1 — 1 — 0 8 3 3 — 0 5 — 5
Vermont§ — 0 1 — — — 0 1 2 5 — 1 5 8 10
Mid. Atlantic — 2 6 11 16 8 20 43 80 184 9 10 23 68 87
New Jersey — 0 2 — 1 — 2 8 — 48 — 0 0 — —
New York (Upstate) — 0 3 2 — 7 5 29 36 22 9 8 22 58 39
New York City — 0 2 4 4 — 0 11 — 12 — 0 7 10 —
Pennsylvania — 1 3 5 11 1 9 29 44 102 — 0 16 — 48
E.N. Central 2 2 9 21 45 25 53 100 351 532 — 2 19 5 7
Illinois — 0 4 3 10 — 11 29 24 134 — 1 9 1 1
Indiana — 0 3 5 8 — 6 15 16 73 — 0 7 — 1
Michigan — 0 5 2 5 5 15 41 112 111 — 1 6 2 5
Ohio 2 1 3 8 13 20 19 49 194 191 — 0 5 2 —
Wisconsin — 0 1 3 9 — 2 12 5 23 N 0 0 N N
W.N. Central 1 1 6 8 15 — 31 503 101 371 2 7 18 25 35
Iowa — 0 2 1 1 — 3 10 19 38 — 0 3 — 3
Kansas — 0 2 1 3 — 5 12 20 33 — 1 6 9 14
Minnesota 1 0 2 1 4 — 0 498 — — — 0 11 8 5
Missouri — 0 3 4 7 — 14 47 48 249 — 1 5 1 1
Nebraska§ — 0 1 1 — — 2 9 11 44 2 1 6 7 7
North Dakota — 0 1 — — — 0 12 — 1 — 0 7 — 2
South Dakota — 0 1 — — — 0 6 3 6 — 0 4 — 3
S. Atlantic 1 3 10 29 27 9 29 66 132 281 14 22 103 133 342
Delaware — 0 1 1 — — 0 2 — 4 — 0 0 — —
District of Columbia — 0 0 — — — 0 1 — 3 — 0 0 — —
Florida 1 1 4 14 13 4 7 29 36 60 3 0 5 24 156
Georgia — 0 2 3 4 — 4 22 28 36 — 0 72 — 61
Maryland§ — 0 1 1 1 3 3 8 26 16 10 7 15 48 47
North Carolina — 0 10 — 5 — 0 21 — 112 N 0 4 N N
South Carolina§ — 0 1 2 2 1 4 18 28 23 — 0 0 — —
Virginia§ — 0 2 7 2 1 3 15 13 24 — 10 26 50 73
West Virginia — 0 2 1 — — 0 5 1 3 1 3 6 11 5
E.S. Central — 0 4 5 2 2 14 30 100 130 — 1 6 — 28
Alabama§ — 0 2 1 — 2 5 19 28 22 — 0 0 — —
Kentucky — 0 1 2 — — 3 15 35 66 — 0 2 — 12
Mississippi — 0 1 1 — — 1 6 3 15 — 0 1 — —
Tennessee§ — 0 2 1 2 — 4 9 34 27 — 0 4 — 16
W.S. Central 1 1 8 9 19 1 66 624 90 170 5 0 13 5 4
Arkansas§ — 0 2 2 3 — 6 23 2 17 3 0 10 3 2
Louisiana — 0 1 — 8 — 0 8 — 18 — 0 0 — —
Oklahoma 1 0 2 4 1 1 0 32 1 6 2 0 13 2 2
Texas§ — 1 7 3 7 — 55 614 87 129 — 0 1 — —
Mountain 1 1 4 7 15 1 16 39 102 196 — 1 6 4 17
Arizona — 0 2 3 3 — 5 15 24 21 N 0 0 N N
Colorado — 0 3 1 5 — 4 10 17 48 — 0 0 — —
Idaho§ 1 0 1 1 3 1 1 19 37 17 — 0 0 — —
Montana§ — 0 2 — 1 — 1 6 4 5 — 0 4 — 5
Nevada§ — 0 1 1 1 — 0 3 — 2 — 0 1 — —
New Mexico§ — 0 1 1 1 — 1 5 14 24 — 0 2 1 6
Utah — 0 1 — 1 — 2 11 5 77 — 0 2 — —
Wyoming§ — 0 2 — — — 0 5 1 2 — 0 4 3 6
Pacific 4 3 13 29 35 9 23 42 54 104 2 4 13 17 22
Alaska — 0 2 — 2 — 1 4 5 16 — 0 2 6 8
California 2 2 10 19 17 1 11 23 4 29 2 4 11 10 14
Hawaii — 0 1 — 1 — 0 3 — 6 — 0 0 — —
Oregon — 1 6 7 10 — 4 13 30 42 — 0 3 1 —
Washington 2 0 6 3 5 8 5 33 15 11 — 0 0 — —
American Samoa — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 1 — — 3 1 3 12 9
U.S. Virgin Islands — 0 0 — — — 0 0 — — N 0 0 N N
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Reporting area
Salmonellosis Shiga toxin-producing E. coli (STEC)† Shigellosis
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 307 893 1,374 3,572 5,639 15 82 154 225 497 85 273 496 1,530 2,589
New England — 30 90 81 620 — 3 30 5 80 — 4 27 13 71
Connecticut — 0 46 46 429 — 0 3 3 67 — 0 9 9 43
Maine§ — 2 7 7 15 — 0 3 — — — 0 2 1 2
Massachusetts — 20 47 — 127 — 2 7 — 7 — 3 27 — 22
New Hampshire — 3 44 14 24 — 1 3 2 6 — 0 4 2 1
Rhode Island§ — 2 11 12 16 — 0 26 — — — 0 7 1 3
Vermont§ — 1 5 2 9 — 0 3 — — — 0 1 — —
Mid. Atlantic 38 90 206 415 593 — 6 21 23 40 17 47 87 262 508
New Jersey — 13 46 23 98 — 0 4 — 9 — 6 27 13 168
New York (Upstate) 24 23 77 118 137 — 3 11 10 14 6 4 19 29 20
New York City — 22 46 119 153 — 1 5 4 7 — 7 15 40 93
Pennsylvania 14 29 65 155 205 — 2 8 9 10 11 25 63 180 227
E.N. Central 13 92 153 339 793 — 13 36 28 101 2 39 78 115 625
Illinois — 24 52 74 207 — 3 6 5 44 — 9 34 26 125
Indiana — 7 20 8 54 — 1 8 — 8 — 1 5 1 16
Michigan 1 17 34 84 148 — 3 8 12 11 — 4 11 24 58
Ohio 12 24 52 139 223 — 2 11 5 13 2 13 46 52 339
Wisconsin — 11 30 34 161 — 4 21 6 25 — 5 26 12 87
W.N. Central 17 47 86 236 398 2 12 39 39 44 1 29 86 412 90
Iowa 5 6 16 28 58 — 2 14 3 10 — 0 5 7 27
Kansas — 6 22 33 50 — 1 5 4 2 — 3 13 20 31
Minnesota 10 11 30 66 81 2 2 19 13 13 1 1 7 8 11
Missouri — 12 30 76 61 — 2 10 15 12 — 20 72 375 13
Nebraska§ 2 5 41 24 83 — 1 6 4 7 — 0 3 2 7
North Dakota — 0 21 2 5 — 0 3 — — — 0 2 — —
South Dakota — 1 15 7 60 — 0 12 — — — 0 1 — 1
S. Atlantic 142 278 453 1,328 1,401 8 12 22 52 84 24 41 79 252 403
Delaware 1 2 9 7 5 — 0 2 — 2 — 3 10 20 4
District of Columbia — 0 2 4 10 — 0 0 — 1 — 0 2 1 3
Florida 62 133 278 643 568 4 3 7 19 30 14 9 18 95 88
Georgia 8 45 98 231 235 — 1 4 8 7 — 12 29 85 99
Maryland§ 13 15 32 89 112 — 2 5 8 11 6 5 17 15 75
North Carolina 49 14 89 169 237 1 0 11 1 22 1 3 27 7 57
South Carolina§ 2 16 67 69 102 — 0 3 1 3 — 2 6 14 36
Virginia§ 6 20 65 100 110 3 3 7 15 7 3 3 14 15 36
West Virginia 1 4 23 16 22 — 0 5 — 1 — 0 2 — 5
E.S. Central 5 52 113 184 337 1 4 10 11 23 2 12 46 55 147
Alabama§ — 14 39 46 109 — 1 4 5 4 — 2 9 5 42
Kentucky 1 7 18 43 66 — 1 4 — 8 2 3 25 31 18
Mississippi — 14 45 28 74 — 0 1 2 2 — 1 4 2 5
Tennessee§ 4 14 33 67 88 1 1 8 4 9 — 5 16 17 82
W.S. Central 9 100 369 149 388 — 5 23 9 21 17 47 150 205 378
Arkansas§ 4 10 25 24 64 — 1 4 4 5 1 5 14 9 36
Louisiana — 4 43 — 65 — 0 0 — — — 0 7 — 45
Oklahoma 5 11 30 36 41 — 0 6 1 4 3 6 19 35 27
Texas§ — 57 350 89 218 — 4 23 4 12 13 31 124 161 270
Mountain 21 51 118 308 388 3 7 28 26 62 7 18 43 85 191
Arizona 7 20 57 109 150 1 1 5 5 1 6 14 37 48 129
Colorado 12 10 33 90 79 — 2 11 3 44 1 2 6 19 22
Idaho§ 1 3 10 22 25 1 1 7 7 4 — 0 1 2 —
Montana§ — 2 7 19 18 1 0 7 2 — — 0 4 2 —
Nevada§ — 3 11 13 25 — 0 3 1 1 — 1 7 1 17
New Mexico§ — 5 28 28 30 — 1 3 5 8 — 1 8 10 21
Utah — 6 14 17 54 — 1 11 3 3 — 0 4 3 2
Wyoming§ 1 1 9 10 7 — 0 2 — 1 — 0 1 — —
Pacific 62 123 344 532 721 1 9 73 32 42 15 22 61 131 176
Alaska — 1 7 11 9 — 0 0 — — — 0 2 — 1
California 41 93 200 428 566 1 4 23 23 35 13 18 40 119 148
Hawaii — 5 61 — 45 — 0 2 — 1 — 0 4 — 6
Oregon — 8 19 44 63 — 1 11 4 1 — 1 4 6 9
Washington 21 11 132 49 38 — 2 48 5 5 2 2 19 6 12
American Samoa — 0 1 1 — — 0 0 — — — 0 2 — 3
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 5 19 32 98 — 0 0 — — — 0 2 — 1
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes E. coli O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*











Previous 52 weeks Cum  
2010
Cum  
2009Med Max Med Max
United States 4 2 9 10 5 6 17 73 34 122
New England — 0 1 — — — 0 2 — 1
Connecticut — 0 0 — — — 0 0 — —
Maine§ — 0 0 — — — 0 2 — 1
Massachusetts — 0 1 — — — 0 1 — —
New Hampshire — 0 0 — — — 0 1 — —
Rhode Island§ — 0 0 — — — 0 0 — —
Vermont§ — 0 1 — — — 0 0 — —
Mid. Atlantic 1 0 3 1 — — 1 6 — 4
New Jersey — 0 0 — — — 0 0 — —
New York (Upstate) — 0 1 — — — 0 3 — —
New York City — 0 1 — — — 0 4 — 3
Pennsylvania 1 0 2 1 — — 0 2 — 1
E.N. Central — 0 2 — 1 — 1 7 — 3
Illinois — 0 0 — — — 0 6 — 1
Indiana — 0 2 — — — 0 2 — —
Michigan — 0 1 — 1 — 0 1 — —
Ohio — 0 0 — — — 0 4 — 2
Wisconsin — 0 0 — — — 0 1 — —
W.N. Central — 0 3 — — — 3 27 2 1
Iowa — 0 1 — — — 0 1 — —
Kansas — 0 1 — — — 0 0 — —
Minnesota — 0 1 — — — 0 1 — —
Missouri — 0 1 — — — 3 26 2 1
Nebraska§ — 0 2 — — — 0 1 — —
North Dakota — 0 0 — — — 0 0 — —
South Dakota — 0 0 — — — 0 0 — —
S. Atlantic — 1 9 4 3 — 5 25 18 101
Delaware — 0 0 — — — 0 3 — 1
District of Columbia — 0 0 — — — 0 0 — —
Florida — 0 1 — — — 0 2 — 1
Georgia — 0 7 4 3 — 0 0 — —
Maryland§ — 0 1 — — — 0 3 — 7
North Carolina — 0 1 — — — 2 24 15 81
South Carolina§ — 0 1 — — — 0 4 2 4
Virginia§ — 0 1 — — — 0 5 1 6
West Virginia — 0 0 — — — 0 1 — 1
E.S. Central 1 0 2 1 1 — 4 15 — 8
Alabama§ — 0 1 — — — 1 7 — 4
Kentucky 1 0 1 1 — — 0 0 — —
Mississippi — 0 0 — 1 — 0 1 — —
Tennessee§ — 0 2 — — — 2 14 — 4
W.S. Central — 0 3 1 — — 1 25 2 2
Arkansas§ — 0 0 — — — 0 14 — 1
Louisiana — 0 0 — — — 0 1 — —
Oklahoma — 0 3 — — — 0 24 — —
Texas§ — 0 1 1 — — 0 8 2 1
Mountain 2 0 2 3 — 6 0 4 12 2
Arizona 2 0 1 3 — 6 0 4 12 —
Colorado — 0 1 — — — 0 0 — —
Idaho§ — 0 0 — — — 0 1 — —
Montana§ — 0 1 — — — 0 2 — —
Nevada§ — 0 0 — — — 0 0 — —
New Mexico§ — 0 0 — — — 0 0 — 1
Utah — 0 0 — — — 0 0 — 1
Wyoming§ — 0 1 — — — 0 1 — —
Pacific — 0 1 — — — 0 0 — —
Alaska — 0 0 — — — 0 0 — —
California — 0 1 — — — 0 0 — —
Hawaii — 0 0 — — — 0 0 — —
Oregon — 0 0 — — — 0 0 — —
Washington — 0 0 — — — 0 0 — —
American Samoa — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — —
Guam — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Illnesses with similar clinical presentation that result from Spotted fever group rickettsia infections are reported as Spotted fever rickettsioses. Rocky Mountain spotted fever (RMSF) caused 
by Rickettsia rickettsii, is the most common and well-known spotted fever.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
Streptococcus pneumoniae,† invasive disease
Reporting area
All ages Age <5 Syphilis, primary and secondary
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 233 55 346 2,424 757 33 43 108 364 519 72 264 325 1,442 2,464
New England 3 1 50 72 16 — 1 23 6 11 4 6 21 60 53
Connecticut — 0 50 — — — 0 22 — — — 1 9 11 7
Maine§ — 0 4 16 3 — 0 2 3 — — 0 2 5 1
Massachusetts — 0 1 — — — 0 5 — 8 2 4 12 33 38
New Hampshire 2 0 6 31 5 — 0 2 3 2 — 0 1 2 7
Rhode Island§ — 0 3 6 4 — 0 1 — — 2 0 5 7 —
Vermont§ 1 0 6 19 4 — 0 1 — 1 — 0 2 2 —
Mid. Atlantic 12 4 25 135 30 4 5 33 51 46 11 33 50 246 326
New Jersey — 0 4 14 — — 0 4 9 10 5 3 13 29 39
New York (Upstate) 3 2 18 38 15 2 2 18 27 27 3 2 10 13 13
New York City — 0 1 — 1 — 0 14 — 6 — 20 39 152 223
Pennsylvania 9 2 19 83 14 2 0 5 15 3 3 7 14 52 51
E.N. Central 12 13 64 369 151 1 8 15 55 97 — 24 48 83 228
Illinois — 0 0 — — — 1 4 — 14 — 11 33 5 121
Indiana 1 4 14 72 53 — 1 4 9 15 — 2 9 7 30
Michigan 5 0 26 118 7 1 1 5 18 15 — 4 13 38 36
Ohio 6 8 18 88 91 — 2 7 19 38 — 7 13 33 29
Wisconsin — 0 20 91 — — 1 3 9 15 — 0 3 — 12
W.N. Central 38 3 39 166 31 4 3 13 31 33 — 5 12 22 60
Iowa — 0 0 — — — 0 0 — — — 0 2 — 6
Kansas — 1 5 10 17 — 0 2 2 5 — 0 3 — 3
Minnesota 35 0 25 85 — 3 0 10 15 10 — 1 3 5 16
Missouri — 1 8 28 13 — 0 5 10 13 — 3 8 16 33
Nebraska§ 3 0 7 39 — 1 0 2 3 1 — 0 2 1 1
North Dakota — 0 3 — 1 — 0 3 — — — 0 1 — 1
South Dakota — 0 2 4 — — 0 2 1 4 — 0 1 — —
S. Atlantic 80 26 105 732 389 8 10 21 96 152 37 64 152 367 501
Delaware 1 0 2 4 4 — 0 2 — — 1 0 3 1 6
District of Columbia 2 0 2 8 — — 0 1 3 — — 3 8 15 34
Florida 51 14 66 366 233 7 3 11 42 55 2 19 32 113 208
Georgia 9 8 17 111 129 1 3 9 27 49 — 14 103 24 62
Maryland§ 11 0 18 97 2 — 1 7 8 18 6 6 12 34 47
North Carolina — 0 0 — — — 0 0 — — 18 9 31 103 86
South Carolina§ 1 0 24 120 — — 1 4 13 16 — 2 6 26 15
Virginia§ — 0 0 — — — 0 4 — 11 10 6 15 51 42
West Virginia 5 1 19 26 21 — 0 3 3 3 — 0 2 — 1
E.S. Central 22 4 48 233 80 3 2 9 22 34 13 20 37 117 212
Alabama§ — 0 0 — — — 0 0 — — — 7 18 23 80
Kentucky — 1 5 13 21 — 0 2 1 4 2 1 13 16 12
Mississippi — 0 4 7 2 — 0 2 2 5 7 4 12 20 31
Tennessee§ 22 2 42 213 57 3 2 7 19 25 4 7 14 58 89
W.S. Central 34 1 47 263 27 7 6 35 48 61 4 48 74 275 474
Arkansas§ 8 1 5 30 12 2 0 4 8 8 4 6 16 45 13
Louisiana — 0 5 — 15 — 0 3 — 11 — 12 27 64 170
Oklahoma 3 0 5 16 — 3 1 5 16 10 — 1 6 6 16
Texas§ 23 0 42 217 — 2 4 31 24 32 — 31 46 160 275
Mountain 29 2 66 410 31 5 5 13 48 75 — 7 18 41 92
Arizona 14 0 39 226 — 2 2 6 24 35 — 3 9 12 38
Colorado 13 0 20 122 — 1 1 4 13 15 — 1 5 17 19
Idaho§ — 0 1 3 — — 0 2 1 2 — 0 1 — 1
Montana§ — 0 1 3 — — 0 0 — — — 0 1 — —
Nevada§ — 1 4 11 8 — 0 2 2 — — 1 10 10 19
New Mexico§ 2 0 7 33 — 2 0 4 6 5 — 1 4 2 11
Utah — 1 4 9 19 — 1 6 2 18 — 0 2 — 4
Wyoming§ — 0 2 3 4 — 0 1 — — — 0 1 — —
Pacific 3 0 9 44 2 1 0 2 7 10 3 43 63 231 518
Alaska — 0 6 22 — — 0 2 5 7 — 0 0 — —
California 3 0 9 22 — 1 0 1 2 — 2 39 56 207 470
Hawaii — 0 1 — 2 — 0 2 — 3 — 0 2 4 11
Oregon — 0 0 — — — 0 0 — — — 1 5 6 7
Washington — 0 0 — — — 0 0 — — 1 2 7 14 30
American Samoa — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 0 0 — — — 0 0 — — 1 3 17 37 29
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
* Incidence data for reporting years 2009 and 2010 are provisional.
† Includes drug resistant and susceptible cases of invasive Streptococcus pneumoniae disease among children <5 years and among all ages. Case definition: Isolation of S. pneumoniae from 
a normally sterile body site (e.g., blood or cerebrospinal fluid).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
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TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending March 6, 2010, and March 7, 2009 (9th week)*
West Nile virus disease†
Reporting area
Varicella (chickenpox) Neuroinvasive Nonneuroinvasive§
Current 
week












Previous 52 weeks Cum 
2010
Cum 
2009Med Max Med Max Med Max
United States 195 260 638 2,213 4,599 — 1 46 1 — — 0 48 — —
New England 3 14 33 84 165 — 0 0 — — — 0 0 — —
Connecticut — 8 23 18 91 — 0 0 — — — 0 0 — —
Maine¶ — 0 15 30 — — 0 0 — — — 0 0 — —
Massachusetts — 0 2 — — — 0 0 — — — 0 0 — —
New Hampshire 3 3 10 23 47 — 0 0 — — — 0 0 — —
Rhode Island¶** — 0 1 1 3 — 0 0 — — — 0 0 — —
Vermont¶** — 0 4 12 24 — 0 0 — — — 0 0 — —
Mid. Atlantic 11 25 55 177 387 — 0 2 — — — 0 1 — —
New Jersey N 0 0 N N — 0 1 — — — 0 0 — —
New York (Upstate) N 0 0 N N — 0 1 — — — 0 1 — —
New York City — 0 0 — — — 0 1 — — — 0 0 — —
Pennsylvania 11 25 55 177 387 — 0 0 — — — 0 0 — —
E.N. Central 81 103 206 939 1,752 — 0 4 — — — 0 3 — —
Illinois 4 25 64 165 452 — 0 3 — — — 0 0 — —
Indiana 11 7 30 125 92 — 0 1 — — — 0 1 — —
Michigan 28 35 84 298 517 — 0 1 — — — 0 0 — —
Ohio 38 29 85 282 552 — 0 0 — — — 0 2 — —
Wisconsin — 8 57 69 139 — 0 1 — — — 0 0 — —
W.N. Central — 10 43 73 294 — 0 5 — — — 0 11 — —
Iowa N 0 0 N N — 0 0 — — — 0 1 — —
Kansas** — 2 19 1 65 — 0 1 — — — 0 2 — —
Minnesota — 0 0 — — — 0 1 — — — 0 1 — —
Missouri — 7 33 62 202 — 0 2 — — — 0 1 — —
Nebraska¶** N 0 0 N N — 0 2 — — — 0 6 — —
North Dakota — 0 26 8 23 — 0 0 — — — 0 1 — —
South Dakota — 0 2 2 4 — 0 3 — — — 0 2 — —
S. Atlantic 38 23 95 302 504 — 0 4 — — — 0 1 — —
Delaware — 0 2 1 2 — 0 0 — — — 0 0 — —
District of Columbia — 0 3 — 5 — 0 0 — — — 0 0 — —
Florida 35 14 61  181 283 — 0 1 — — — 0 1 — —
Georgia N 0 0 N N — 0 1 — — — 0 0 — —
Maryland¶ N 0 0 N N — 0 0 — — — 0 1 — —
North Carolina N 0 0 N N — 0 0 — — — 0 0 — —
South Carolina¶** 3 0 12 12 102 — 0 2 — — — 0 0 — —
Virginia¶** — 0 5 38 28 — 0 1 — — — 0 0 — —
West Virginia — 9 32 70 84 — 0 0 — — — 0 0 — —
E.S. Central 1 7 29 31 114 — 0 6 1 — — 0 4 — —
Alabama¶** 1 7 27 31 114 — 0 0 — — — 0 0 — —
Kentucky N 0 0 N N — 0 1 — — — 0 0 — —
Mississippi — 0 2 — — — 0 5 1 — — 0 4 — —
Tennessee¶ N 0 0 N N — 0 2 — — — 0 1 — —
W.S. Central 46 66 261 401 921 — 0 19 — — — 0 6 — —
Arkansas¶** — 0 23 11 39 — 0 1 — — — 0 0 — —
Louisiana — 0 7 — 13 — 0 2 — — — 0 4 — —
Oklahoma N 0 0 N N — 0 2 — — — 0 2 — —
Texas¶** 46 65 245 390 869 — 0 16 — — — 0 4 — —
Mountain 15 17 62 203 424 — 0 12 — — — 0 17 — —
Arizona — 0 0 — — — 0 4 — — — 0 2 — —
Colorado 12 7 22 91 154 — 0 7 — — — 0 14 — —
Idaho¶ N 0 0 N N — 0 3 — — — 0 5 — —
Montana¶** 3 0 10 46 64 — 0 1 — — — 0 1 — —
Nevada¶ N 0 0 N N — 0 2 — — — 0 1 — —
New Mexico¶** — 0 12 16 64 — 0 2 — — — 0 1 — —
Utah — 7 32 50 142 — 0 1 — — — 0 1 — —
Wyoming¶ — 0 0 — — — 0 1 — — — 0 2 — —
Pacific — 1 5 3 38 — 0 12 — — — 0 12 — —
Alaska — 0 4 3 23 — 0 0 — — — 0 0 — —
California — 0 0 — — — 0 8 — — — 0 6 — —
Hawaii — 0 4 — 15 — 0 0 — — — 0 0 — —
Oregon N 0 0 N N — 0 1 — — — 0 4 — —
Washington N 0 0 N N — 0 6 — — — 0 3 — —
American Samoa N 0 0 N N — 0 0 — — — 0 0 — —
C.N.M.I. — — — — — — — — — — — — — — —
Guam — 0 0 — — — 0 0 — — — 0 0 — —
Puerto Rico — 5 26 40 73 — 0 0 — — — 0 0 — —
U.S. Virgin Islands — 0 0 — — — 0 0 — — — 0 0 — —
C.N.M.I.: Commonwealth of Northern Mariana Islands.
U: Unavailable.   —: No reported cases.   N: Not reportable.   NN: Not Nationally Notifiable.   Cum: Cumulative year-to-date counts.   Med: Median.   Max: Maximum.
 * Incidence data for reporting years 2009 and 2010 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly.
 † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California 
serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.
 § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-
associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
 ¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
 ** Contains data that was reported via HL7 messages.
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TABLE III. Deaths in 122 U.S. cities,* week ending March 6, 2010 (9th week)
Reporting area
All causes, by age (years)
P&I† 
Total Reporting area




Ages ≥65 45–64 25–44 1–24 <1
All  
Ages ≥65 45–64 25–44 1–24 <1
New England 560 396 113 27 13 11 62 S. Atlantic 1,250 834 300 70 19 27 94
Boston, MA 140 92 32 6 4 6 11 Atlanta, GA 194 132 43 10 4 5 13
Bridgeport, CT 45 37 5 1 2 — 5 Baltimore, MD 181 100 59 14 2 6 19
Cambridge, MA 8 5 3 — — — 2 Charlotte, NC 114 83 21 2 3 5 9
Fall River, MA 27 22 3 2 — — 5 Jacksonville, FL 148 102 36 9 1 — 12
Hartford, CT 57 44 4 6 3 — 8 Miami, FL 118 73 29 9 5 2 4
Lowell, MA 25 20 4 1 — — 6 Norfolk, VA 60 40 16 2 — 2 2
Lynn, MA 8 4 2 2 — — — Richmond, VA 64 43 17 2 2 — 6
New Bedford, MA 26 17 8 1 — — 3 Savannah, GA 59 44 12 1 — 2 4
New Haven, CT 32 25 4 2 1 — 5 St. Petersburg, FL 66 45 11 6 — 4 5
Providence, RI 59 45 11 1 1 1 3 Tampa, FL 232 163 52 14 2 1 19
Somerville, MA 4 3 1 — — — — Washington, D.C. U U U U U U U
Springfield, MA 35 21 8 2 — 4 4 Wilmington, DE 14 9 4 1 — — 1
Waterbury, CT 33 21 10 — 2 — 3 E.S. Central 1,090 729 252 70 22 17 90
Worcester, MA 61 40 18 3 — — 7 Birmingham, AL 207 138 47 12 4 6 18
Mid. Atlantic 2,160 1,492 491 119 29 29 125 Chattanooga, TN 77 60 14 1 2 — 4
Albany, NY 41 35 5 — 1 — 3 Knoxville, TN 146 93 36 12 2 3 7
Allentown, PA 25 21 4 — — — 2 Lexington, KY 68 46 16 3 1 2 12
Buffalo, NY 79 56 15 5 2 1 7 Memphis, TN 192 131 47 10 2 2 22
Camden, NJ 28 13 9 3 1 2 — Mobile, AL 196 136 39 16 5 — 15
Elizabeth, NJ 20 12 4 2 2 — 1 Montgomery, AL 52 31 15 3 2 1 4
Erie, PA 49 40 6 3 — — 6 Nashville, TN 152 94 38 13 4 3 8
Jersey City, NJ 38 25 12 1 — — 4 W.S. Central 1,195 759 310 69 23 34 93
New York City, NY 1,062 744 236 51 15 16 50 Austin, TX 72 47 17 4 3 1 8
Newark, NJ 36 19 9 5 — 3 3 Baton Rouge, LA 60 41 16 2 1 — —
Paterson, NJ 35 22 6 6 1 — 4 Corpus Christi, TX 57 37 15 2 3 — 2
Philadelphia, PA 412 265 110 29 4 4 21 Dallas, TX 213 130 54 13 4 12 23
Pittsburgh, PA§ 39 27 7 3 2 — 3 El Paso, TX 75 45 23 7 — — 5
Reading, PA 40 32 8 — — — 2 Fort Worth, TX U U U U U U U
Rochester, NY 77 53 17 5 — 2 9 Houston, TX 180 105 54 12 3 6 15
Schenectady, NY 23 14 9 — — — 3 Little Rock, AR 60 37 19 2 — 2 4
Scranton, PA 33 24 8 1 — — — New Orleans, LA U U U U U U U
Syracuse, NY 60 44 14 1 — 1 3 San Antonio, TX 283 189 63 16 7 8 23
Trenton, NJ 26 14 7 4 1 — — Shreveport, LA 82 51 24 4 — 3 5
Utica, NY 20 17 3 — — — 1 Tulsa, OK 113 77 25 7 2 2 8
Yonkers, NY 17 15 2 — — — 3 Mountain 1,227 836 267 86 19 19 81
E.N. Central 2,236 1,510 519 117 44 46 149 Albuquerque, NM 120 82 23 10 4 1 11
Akron, OH 57 37 12 4 — 4 5 Boise, ID 58 39 14 4 — 1 3
Canton, OH 32 20 11 1 — — 4 Colorado Springs, CO 82 57 19 5 — 1 7
Chicago, IL 329 222 74 22 7 4 15 Denver, CO 84 57 12 8 1 6 10
Cincinnati, OH 88 57 20 5 4 2 6 Las Vegas, NV 303 207 81 11 3 1 12
Cleveland, OH 232 172 46 7 4 3 11 Ogden, UT 43 32 7 4 — — 1
Columbus, OH 290 194 64 17 6 9 26 Phoenix, AZ 173 106 37 20 6 4 10
Dayton, OH 120 78 31 7 1 3 12 Pueblo, CO 26 24 1 1 — — 1
Detroit, MI 168 99 50 10 5 4 8 Salt Lake City, UT 136 87 31 15 2 1 10
Evansville, IN 46 32 11 3 — — 1 Tucson, AZ 202 145 42 8 3 4 16
Fort Wayne, IN 75 49 17 7 1 1 3 Pacific 1,690 1,218 343 79 27 23 194
Gary, IN 15 6 5 2 1 1 1 Berkeley, CA 17 10 7 — — — 1
Grand Rapids, MI 67 51 11 1 2 2 12 Fresno, CA 130 97 24 6 1 2 15
Indianapolis, IN 248 164 62 9 3 10 22 Glendale, CA 40 31 8 1 — — 13
Lansing, MI 41 32 6 2 1 — 2 Honolulu, HI 38 31 6 1 — — 5
Milwaukee, WI 118 80 30 7 — 1 8 Long Beach, CA 72 51 13 7 1 — 14
Peoria, IL 46 32 9 2 2 1 5 Los Angeles, CA 236 156 58 14 5 3 29
Rockford, IL 53 40 7 4 2 — 2 Pasadena, CA 18 17 1 — — — 3
South Bend, IN 52 39 9 2 1 1 3 Portland, OR 114 77 28 4 4 1 6
Toledo, OH 95 59 28 4 4 — 1 Sacramento, CA 200 151 37 10 1 1 33
Youngstown, OH 64 47 16 1 — — 2 San Diego, CA 169 116 34 9 2 8 22
W.N. Central 597 402 136 36 9 14 39 San Francisco, CA 126 84 33 6 1 2 12
Des Moines, IA 49 32 7 8 — 2 4 San Jose, CA 198 148 40 4 2 4 21
Duluth, MN 32 26 5 1 — — 1 Santa Cruz, CA 28 23 5 — — — 2
Kansas City, KS 19 10 6 2 — 1 1 Seattle, WA 117 84 19 7 5 2 6
Kansas City, MO 122 77 31 7 2 5 7 Spokane, WA 67 54 10 2 1 — 3
Lincoln, NE 54 36 15 2 — 1 5 Tacoma, WA 120 88 20 8 4 — 9
Minneapolis, MN 77 51 19 4 3 — 5 Total¶ 12,005 8,176 2,731 673 205 220 927
Omaha, NE 96 68 22 3 1 2 10
St. Louis, MO 5 2 1 1 — 1 —
St. Paul, MN 53 40 11 1 1 — 2
Wichita, KS 90 60 19 7 2 2 4
U: Unavailable.   —: No reported cases.   
* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and 
by the week that the death certificate was filed. Fetal deaths are not included.
† Pneumonia and influenza.
§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
¶ Total includes unknown ages.
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